睿知中国医院研究地图
候选清单

成都四川大学华西

四川大学华西医院

West China Hospital

在本站收录的 53 种疾病中,这家医院列在其中 46 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

四川大学华西医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma44 篇牵头论文牵头 2 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma71 篇牵头论文牵头 6 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma392 篇牵头论文牵头 16 项开放试验
  4. 胃癌Stomach cancer168 篇牵头论文牵头 4 项开放试验
  5. 肝母细胞瘤Hepatoblastoma4 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  7. 脊索瘤Chordoma3 篇牵头论文
  8. 骨肉瘤Osteosarcoma36 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour33 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma5 篇牵头论文牵头 2 项开放试验
  11. 尤文肉瘤Ewing sarcoma9 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma59 篇牵头论文
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia1 篇牵头论文
  14. 再生障碍性贫血Aplastic anaemia4 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis12 篇牵头论文
  16. β 地中海贫血Beta thalassaemia2 篇牵头论文
  17. 血友病 AHaemophilia A4 篇牵头论文
  18. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
  19. 范可尼贫血Fanconi anaemia1 篇牵头论文
  20. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder36 篇牵头论文
  21. IgG4相关性疾病IgG4-related disease11 篇牵头论文
  22. 重症肌无力Myasthenia gravis16 篇牵头论文
  23. 烟雾病Moyamoya disease11 篇牵头论文
  24. 胆道闭锁Biliary atresia7 篇牵头论文
  25. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis22 篇牵头论文
  26. 大动脉炎Takayasu arteritis3 篇牵头论文
  27. 肝包虫病Hepatic echinococcosis14 篇牵头论文
  28. 特发性肺纤维化Idiopathic pulmonary fibrosis31 篇牵头论文
  29. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis2 篇牵头论文
  30. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis60 篇牵头论文
  31. 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
  32. 法布雷病Fabry disease5 篇牵头论文
  33. 庞贝病Pompe disease2 篇牵头论文
  34. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  35. 白塞病Behçet disease6 篇牵头论文
  36. Alport 综合征Alport syndrome2 篇牵头论文
  37. IgA 肾病IgA nephropathy34 篇牵头论文
  38. 戈谢病Gaucher disease0 篇牵头论文
  39. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  40. 原发性胆汁性胆管炎Primary biliary cholangitis11 篇牵头论文
  41. 原发性硬化性胆管炎Primary sclerosing cholangitis3 篇牵头论文
  42. 先天性膈疝Congenital diaphragmatic hernia5 篇牵头论文
  43. 先天性巨结肠Hirschsprung disease1 篇牵头论文
  44. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa4 篇牵头论文
  45. 遗传性血管性水肿Hereditary angioedema2 篇牵头论文
  46. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:非典型溶血性尿毒症综合征、肝豆状核变性、尼曼-匹克病 C 型、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 44 篇,占 1.8%。

牵头论文
44
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 9920222023: 7720232024: 5520242025: 10102025

成都有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
    分期
    I期
    开始
    2026-03
    登记号
    NCT07625423

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:四川大学华西医院成都

  2. 正在招募
    A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
    分期
    I/II期
    开始
    2025-06
    登记号
    NCT07035626

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  3. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  4. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  5. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  6. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  7. 正在招募
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06349889

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心厦门、广州、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题复发与转移放疗技术诱导/同步化疗
论文中的科室放疗科肿瘤内科耳鼻喉/头颈外科影像/核医学科
牵头的论文44
  1. Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.2026International journal of radiation oncology, biology, physics
  2. Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.2026Small (Weinheim an der Bergstrasse, Germany)
  3. Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.2025Cancer immunology, immunotherapy : CIIRCT免费全文
  4. Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).2025Cancer immunology, immunotherapy : CII免费全文
  5. Head-to-Head Comparison of 68 Ga-DOTATATE and 18 F-FDG PET in EBV-Positive Nonkeratinizing Nasopharyngeal Carcinoma.2025Clinical nuclear medicine
  6. Neutrophil-to-Lymphocyte Ratio as a Predictor for PD-L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma.2025Head & neck
  7. Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity-Modulated Radiotherapy.2025Head & neck
  8. Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis.2025International immunopharmacology
  9. Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.2025Oral oncologyRCT
  10. Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.2025Oral oncology
  11. Unveiling the complex double-edged sword role of exosomes in nasopharyngeal carcinoma.2025PeerJ免费全文
  12. Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  13. Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  14. Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.2024Cancer medicine免费全文
  15. Association between time from diagnosis to treatment and survival of patients with nasopharyngeal carcinoma: A population-based cohort study.2024Current problems in cancer
  16. Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.2024Oral oncology
  17. Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.2024Oral oncology
  18. Incidence and Risk Factors for Radiotherapy-Induced Oral Mucositis Among Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.2023Asian nursing research
  19. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.2023Cancer medicine免费全文
  20. Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.2023Clinical nuclear medicine
  21. A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.2023Frontiers of medicine
  22. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.2023Head & neck
  23. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion.2023Journal of nanobiotechnology免费全文
  24. Screening of core genes and prediction of ceRNA regulation mechanism of circRNAs in nasopharyngeal carcinoma by bioinformatics analysis.2023Pathology oncology research : POR免费全文
  25. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.2022Aging免费全文
  26. Acquired unilateral alopecia after arterial infusion chemotherapy in a recurrent nasopharyngeal carcinoma.2022Cancer reports (Hoboken, N.J.)免费全文
  27. Quantitative Comparisons of Deep-learning-based and Atlas-based Auto- segmentation of the Intermediate Risk Clinical Target Volume for Nasopharyngeal Carcinoma.2022Current medical imaging
  28. Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma.2022Frontiers in public health免费全文
  29. Local radiotherapy versus nonradiotherapy to distant lesions for metastatic nasopharyngeal carcinoma: Retrospective cohort study.2022Head & neck
  30. The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis.2022Head & neck
  31. Automatic Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing a Novel Semisupervised Learning Framework in Nasopharyngeal Carcinoma.2022International journal of radiation oncology, biology, physics
  32. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.2022Oral oncology
  33. Computed tomography-based deep-learning prediction of induction chemotherapy treatment response in locally advanced nasopharyngeal carcinoma.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  34. A nomogram for predicting late radiation-induced xerostomia among locoregionally advanced nasopharyngeal carcinoma in intensity modulated radiation therapy era.2021Aging免费全文
  35. Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era.2021BMC cancer免费全文
  36. IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.2021Cell cycle (Georgetown, Tex.)免费全文
  37. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.2021Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  38. m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.2021Frontiers in immunology免费全文
  39. Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma.2021Head & neck免费全文
  40. Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: Meta-analysis.2021Head & neck
  41. Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: A study based on Epstein-Barr virus DNA biological responses.2021Head & neck
  42. Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein-Barr virus DNA.2021Head & neck
  43. Weight Change Trajectory in Patients With Locally Advanced Nasopharyngeal Carcinoma During the Peri-Radiation Therapy Period.2021Oncology nursing forum
  44. A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.2021Radiation oncology (London, England)免费全文
中文论文(未计入)1
  1. [Formulation of the Best Practice Evidence-Based Nutrition Management Protocol for Nasopharyngeal Carcinoma Patients Undergoing Chemoradiotherapy].2024Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
  1. Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors正在招募NCT07625423牵头方I期2026-03 启动
  2. A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)正在招募NCT07035626牵头方I/II期2025-06 启动
  3. A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy已完成NCT06251050牵头方I/II期2024-03 启动
  4. Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy已完成NCT05918224牵头方II期2022-01 启动
  5. Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT04414566牵头方III期2020-06 启动
  6. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  7. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  8. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  9. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  10. Adebrelimab and Chemoradiotherapy in High-risk LANPC正在招募NCT06349889研究中心II期2024-07 启动
  11. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  12. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  13. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  14. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma状态不明NCT03700476研究中心III期2018-12 启动
  15. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  16. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
  17. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)52
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  2. 728eP Real-world outcomes of a contrast-enhanced ultrasound–integrated follow-up strategy in the management of N3 nasopharyngeal carcinoma after radiotherapy2025Annals of Oncology论文
  3. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  4. Spontaneous resolution of laryngeal contact granuloma following radiotherapy for nasopharyngeal carcinoma: A case report2025Asian Journal of Surgery论文
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncology会议摘要
  6. The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma2025International Journal of Radiation Research论文
  7. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  8. VER-155008-functionalized Au-polydopamine blackspheres for heat shock proteins 70-targeted near-infrared II region photothermal therapy2025Cell Reports Physical Science论文
  9. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncology会议摘要
  10. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  11. Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.2024Journal of Clinical Oncology会议摘要
  12. Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  13. Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  14. Elucidating the Immune Microenvironment and Therapeutic Targets in Nasopharyngeal Carcinoma through Bioinformatics2024Journal of Clinical Pharmacy and Therapeutics论文
  15. Evaluation of Adjuvant Chemotherapy after Induction Chemotherapy and Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Propensity Score-Matched Analysis2024International Journal of Radiation Oncology*Biology*Physics论文
  16. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  17. Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial.2024Journal of Clinical Oncology会议摘要
  18. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncology论文
  19. A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.2023Journal of Clinical Oncology会议摘要
  20. Advancing Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing Source-Free Domain Adaptation in Nasopharyngeal Carcinoma2023Lecture notes in computer science会议论文
  21. Automatic Head-and-Neck Tumor Segmentation in MRI via an End-to-End Adversarial Network2023Neural Processing Letters论文
  22. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  23. Long-Term Outcomes of Stereotactic Body Radiation Therapy with or without PD-1 Inhibitors in Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physics论文
  24. Medicine in Nasopharyngeal Carcinoma2023Springer eBooks书籍章节
  25. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncology会议摘要
  26. Radiation-induced MDM4 contributes to radioresistant nasopharyngeal carcinoma (NPC) via impaired TP53 transcriptional activity and activated BNIP3-mediated mitophagy2023Harvard Dataverse数据集
  27. Research on Longitudinal change trends and influencing factors of eating behaviour in patients with nasopharyngeal carcinoma undergoing radiotherapy2023Research Square预印本
  28. A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2).2022Journal of Clinical Oncology会议摘要
  29. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  30. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figshare数据集
  31. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  32. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  33. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figshare数据集
  34. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  35. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  36. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  37. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  38. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  39. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  40. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figshare数据集
  41. Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.2022Journal of Clinical Oncology会议摘要
  42. Multi-transSP: Multimodal Transformer for Survival Prediction of Nasopharyngeal Carcinoma Patients2022Lecture notes in computer science会议论文
  43. The changes of xerostomia and caries risk induced by radiotherapy under the protection of the personalized PMMA oral stents in nasopharyngeal carcinoma patients: a preliminary prospective study2022Research Square预印本
  44. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figshare数据集
  45. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  46. A Novel Dosimetric Metrics-Based Risk Model to Predict Local Recurrence in Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiation Therapy2021Research Square预印本
  47. DA-DSUnet: Dual Attention-based Dense SU-net for automatic head-and-neck tumor segmentation in MRI images2021Neurocomputing论文
  48. Efficient Semi-supervised Gross Target Volume of Nasopharyngeal Carcinoma Segmentation via Uncertainty Rectified Pyramid Consistency2021Lecture notes in computer science会议论文
  49. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncology会议摘要
  50. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  51. Malposition of a Nasogastric Feeding Tube Into the Right Pleural Cavity of a Nasopharyngeal Carcinoma Patient After Radiotherapy and Chemotherapy: A Case Report2021Research Square预印本
  52. Semi-supervised NPC segmentation with uncertainty and attention guided consistency2021Knowledge-Based Systems论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 71 篇,占 2.4%。

牵头论文
71
2021–2025 年
牵头试验
13
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 151520222023: 161620232024: 161620242025: 10102025

成都有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
    分期
    II期
    开始
    2026-04
    登记号
    NCT07519486

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  2. 正在招募
    A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
    分期
    I/II期
    开始
    2025-09
    登记号
    NCT06753747

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  3. 正在招募
    Oncolytic Virus in Esophageal Squamous Cell Carcinoma
    分期
    I/II期
    开始
    2025-08
    登记号
    NCT07061704

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  4. 正在招募
    Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-06
    登记号
    NCT06446726

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  5. 正在招募
    Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-10
    登记号
    NCT06675201

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  6. 即将招募
    Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
    分期
    I期
    开始
    2025-09
    登记号
    NCT07154108

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  7. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  8. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  9. 即将招募
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07769658

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院;另有 5 家列出的医院为研究中心上海、天津、广州、成都、昆明、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗手术影像与人工智能
论文中的科室消化/肝病科肿瘤内科影像/核医学科放疗科
牵头的论文71
  1. Preoperative Physiological Reserve and Pathological Response as Independent Predictors of Survival in Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy.2026Annals of surgical oncology
  2. Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.2026Cell
  3. 68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.2026European journal of nuclear medicine and molecular imaging
  4. Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study.2026International journal of cancer
  5. Does Pseudo-Lymph Node Skip Metastasis After Neoadjuvant Therapy Affect Esophageal Squamous Cell Carcinoma Outcomes? A Multicenter Study.2025Annals of surgical oncology
  6. Artificial intelligence in endoscopic diagnosis of esophageal squamous cell carcinoma and precancerous lesions.2025Chinese medical journal免费全文
  7. The Efficacy of Time Interval Between Neoadjuvant Chemoimmunotherapy and Surgery on Outcomes in Oesophageal Squamous Cell Carcinoma.2025European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  8. Expression and prognostic value of estrogen-related receptor β alternative splicing isoforms in esophageal squamous cell carcinoma.2025European journal of medical research免费全文
  9. Real-world survival benefit of adding immunotherapy to chemotherapy in esophageal cancer: A large SEER-based analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.2025Frontiers in immunology免费全文
  11. A circRNA promotes esophageal squamous cell carcinoma progression by inhibiting TRIM25-mediated degradation of IGF2BP family members.2025Molecular cancer免费全文
  12. Spatial transcriptomic analysis of tumor microenvironment in esophageal squamous cell carcinoma with HIV infection.2025Molecular cancer免费全文
  13. Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.2025World journal of surgical oncology免费全文
  14. Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy.2025World journal of surgical oncology免费全文
  15. Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.2024BMC cancer免费全文
  16. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.2024British journal of cancer免费全文
  17. Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.2024Cancer medicine免费全文
  18. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.2024Cancer medicine免费全文
  19. A platform of functional studies of ESCC-associated gene mutations identifies the roles of TGFBR2 in ESCC progression and metastasis.2024Cell reports
  20. Mapping of lymph node metastasis from esophageal squamous cell carcinoma after neoadjuvant treatment: a prospective analysis from a high-volume institution in China.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  21. A novel tumor staging system incorporating cN status for stratifying early stage esophageal squamous cell carcinoma patients after trimodal therapy.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  22. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.2024Expert review of clinical immunology
  23. A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma.2024Frontiers in immunology
  24. Does increasing the number of resected lymph nodes really improve the prognosis of patients with esophageal squamous cell carcinoma?2024International journal of surgery (London, England)免费全文
  25. Impact of deep muscle invasion on nodal status and survival in patients with pT2 esophageal squamous cancer.2024Journal of surgical oncology
  26. Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.2024Saudi medical journal免费全文
  27. Prognostic factors for patients with pathologic T1-T2N+ esophageal squamous cell carcinoma: A retrospective study with external validation.2024Surgery
  28. Correlation between tumor budding and the long-term follow-up outcomes after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.2024Surgical endoscopy
  29. Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions - Authors' reply.2024The lancet. Gastroenterology & hepatology
  30. Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial.2024The lancet. Gastroenterology & hepatologyRCT
  31. Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/Chemo/Immunotherapy and Liver Metastasis Inhibition with Nanocarriers.2023ACS nano
  32. Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer.2023Annals of surgical oncology免费全文
  33. ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.2023Annals of surgical oncology
  34. Esophageal squamous cell carcinoma presenting as a submucosal tumor.2023Asian journal of surgery
  35. Pararespiratory and paradigestive lymph node metastases in esophageal squamous cell carcinoma: predicting survival and refining the N staging system.2023BMC cancer免费全文
  36. ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma.2023Cancer letters
  37. Identification and Validation of Co-Expressed Immune-Related Gene Signature Affecting the Pattern of Immune Infiltrating in Esophageal Cancer.2023Combinatorial chemistry & high throughput screening
  38. Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma.2023Critical reviews in oncology/hematology
  39. Artificial intelligence for detecting and delineating a small flat-type early esophageal squamous cell carcinoma under multimodal imaging.2023Endoscopy免费全文
  40. MTHFD1L confers a poor prognosis and malignant phenotype in esophageal squamous cell carcinoma by activating the ERK5 signaling pathway.2023Experimental cell research
  41. Artificial intelligence for detecting and delineating the extent of superficial esophageal squamous cell carcinoma and precancerous lesions under narrow-band imaging (with video).2023Gastrointestinal endoscopy
  42. The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  43. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics.2023Signal transduction and targeted therapy免费全文
  44. Development and validation of a model to determine the risk of esophageal strictures after endoscopic submucosal dissection for esophageal neoplasms.2023Surgical endoscopy
  45. Lymphovascular and Perineural Invasion After Neoadjuvant Therapy in Esophageal Squamous Carcinoma.2023The Annals of thoracic surgery
  46. Risk factors and a predictive nomogram for lymph node metastasis in superficial esophageal squamous cell carcinoma.2023World journal of gastroenterology免费全文
  47. Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.2022Annals of surgical oncology
  48. Overexpressed COL3A1 has prognostic value in human esophageal squamous cell carcinoma and promotes the aggressiveness of esophageal squamous cell carcinoma by activating the NF-κB pathway.2022Biochemical and biophysical research communications
  49. Artificial Intelligence for Detecting and Delineating Margins of Early ESCC Under WLI Endoscopy.2022Clinical and translational gastroenterology免费全文
  50. The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  51. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.2022European journal of medicinal chemistry
  52. Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.2022Frontiers in immunology免费全文
  53. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.2022Frontiers in public health免费全文
  54. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.2022Gut免费全文
  55. A Commentary on "The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation" [Int. J. Surg. (2022International journal of surgery (London, England)
  56. The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation.2022International journal of surgery (London, England)
  57. Artificial intelligence for detecting superficial esophageal squamous cell carcinoma under multiple endoscopic imaging modalities: A multicenter study.2022Journal of gastroenterology and hepatology
  58. Characterization of distinct circular RNA signatures in solid tumors.2022Molecular cancer免费全文
  59. Identifying a confused cell identity for esophageal squamous cell carcinoma.2022Signal transduction and targeted therapy免费全文
  60. Raman spectroscopy and machine learning for the classification of esophageal squamous carcinoma.2022Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  61. Artificial intelligence for diagnosing microvessels of precancerous lesions and superficial esophageal squamous cell carcinomas: a multicenter study.2022Surgical endoscopy免费全文
  62. Prognostic Role of Nodal Skip Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study.2021Annals of surgical oncology
  63. ASO Author Reflections: Nodal Skip Metastasis Is Associated with Survival Benefit in Thoracic Esophageal Squamous Cell Carcinoma.2021Annals of surgical oncology
  64. The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).2021Bioengineered免费全文
  65. PIWIL2 interacting with IKK to regulate autophagy and apoptosis in esophageal squamous cell carcinoma.2021Cell death and differentiation免费全文
  66. Fc fragment of immunoglobulin G receptor IIa (FCGR2A) as a new potential prognostic biomarker of esophageal squamous cell carcinoma.2021Chinese medical journal免费全文
  67. Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.2021Disease markers免费全文
  68. Combination of Modified Free Anterolateral Thigh Skin-Fascia Flap and Pedicled Thoracoacromial Artery Perforator Flap for Entire Circumferential Pharyngoesophageal Defect and External Neck Skin Defect Reconstructions.2021Dysphagia
  69. Role of nodal skip metastasis in patients with mid-thoracic oesophageal squamous cell carcinoma: a propensity score matching study.2021European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  70. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.2021Journal for immunotherapy of cancer免费全文
  71. Surgical Treatment for an Esophageal Carcinoma With a Pancreatic Pseudocyst.2021The Annals of thoracic surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)27
  1. A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma正在招募NCT06753747牵头方I/II期2025-09 启动
  2. Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas进行中,不再招募NCT06654297牵头方I期2024-10 启动
  3. Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas状态不明NCT06225921牵头方I期2023-12 启动
  4. Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC正在招募NCT07519486牵头方(推断)II期2026-04 启动
  5. Oncolytic Virus in Esophageal Squamous Cell Carcinoma正在招募NCT07061704牵头方(推断)I/II期2025-08 启动
  6. Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer即将招募NCT07154108牵头方(推断)I期2025-09 启动
  7. Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma正在招募NCT06446726牵头方(推断)II期2024-06 启动
  8. Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma正在招募NCT06675201牵头方(推断)II期2024-10 启动
  9. Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis已完成NCT07549269牵头方(推断)2026-04 启动
  10. Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma已完成NCT07488624牵头方(推断)2026-03 启动
  11. Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer状态不明NCT06403878牵头方(推断)II期2024-05 启动
  12. Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC状态不明NCT06603402牵头方(推断)II期2023-08 启动
  13. A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC状态不明NCT05317325牵头方(推断)I期2022-04 启动
  14. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  15. Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma即将招募NCT07769658研究中心2026-09 启动
  16. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  17. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  18. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma已完成NCT04974047研究中心II期2021-08 启动
  19. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  20. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  21. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  22. A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors进行中,不再招募NCT04603287研究中心I期2020-04 启动
  23. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  24. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  25. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  26. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  27. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)62
  1. 013. VALUE OF COMBINING THE NUMBER OF LYMPH NODE STATIONS AND TUMOR REGRESSION GRADE IN THE NEOADJUVANT TREATMENT OF ESOPHAGEAL CANCER2025Diseases of the Esophagus论文
  2. 035. THE EFFECT OF SURGICAL INTERVAL POST-NEOADJUVANT CHEMOIMMUNOTHERAPY ON LONG-TERM OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  3. 089. SPECTRAL CT-BASED NON-INVASIVE PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE AND POSTOPERATIVE LYMPH NODE METASTASIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  4. 097. TARGETING FUSOBACTERIUM NUCLEATUM WITH MRNA-LNP VACCINES RESTORES PD-1 SENSITIVITY AND REPROGRAMS THE TUMOR MICROENVIRONMENT IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  5. 121. EFFICIENCY INDEX OF LYMPH NODE DISSECTION FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT THERAPY2025Diseases of the Esophagus论文
  6. 138. MULTI-CENTER CLINICAL ANALYSIS AND SINGLE-CELL SEQUENCING INSIGHTS INTO THE DEVELOPMENTAL MECHANISMS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  7. 142. PREDICTIVE ROLE OF CTDNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT IMMUNOTHERAPY AND CHEMOTHERAPY: A PROSPECTIVE COHORT STUDY2025Diseases of the Esophagus论文
  8. 143. LONG-TERM DYSPHAGIA AND REGURGITATION IN 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS: PREVALENCE, CORRELATES, AND PREDICTIVE MODELS IN A MULTI-CENTER COHORT2025Diseases of the Esophagus论文
  9. 149. DOES PSEUDO-LYMPH NODE SKIP METASTASIS AFTER NEOADJUVANT THERAPY AFFECT ESOPHAGEAL SQUAMOUS CELL CARCINOMA OUTCOMES?—A MULTICENTER STUDY2025Diseases of the Esophagus论文
  10. 206. ENO1 LACTYLATION AS A PROMISING PREDICTIVE BIOMARKER AND THERAPEUTIC TARGET FOR ESCC METASTASIS2025Diseases of the Esophagus论文
  11. 207. LOW-DOSE INVOLVED-FIELD RT, PLUS IMMUNOCHEMOTHERAPY SHOWED EXCELLENT EFFICACY AND LOW TOXICITIES IN UNRESECTABLE LA-ESCC: A PROSPECTIVE PHASE II STUDY2025Diseases of the Esophagus论文
  12. 279. GENOMIC COPY NUMBER IDENTIFIES DRIVER MUTATIONS OF METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  13. 321. CTHRC1-MEDIATED MEGAKARYOCYTE/PLATELET INFILTRATION IN THE TUMOR MICROENVIRONMENT PROMOTES IMMUNOTHERAPY RESISTANCE IN ESCC2025Diseases of the Esophagus论文
  14. 329. COMPARISON OF TWO DIFFERENT END-TO-END HAND-SEWN ANASTOMOSES IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE STUDY2025Diseases of the Esophagus论文
  15. 387. RNA M6A METHYLATION PROMOTES TUMOR DEVELOPMENT AND WASF3 TRANSLATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  16. A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).2025Journal of Clinical Oncology论文
  17. Conversion Surgery for cT4b Esophageal Squamous Cell Carcinoma2025Nihon Kikan Shokudoka Gakkai Kaiho论文
  18. Predictive factors for treatment response to neoadjuvant PD-1 inhibitor and chemotherapy in locally advanced esophageal squamous cell carcinoma2025Asian Journal of Surgery论文
  19. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncology会议摘要
  20. Uniportal versus multiportal video-assisted thoracic surgery for esophageal cancer: a randomized clinical trial2025International Journal of Surgery论文
  21. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncology论文
  22. 235. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY2024Diseases of the Esophagus论文
  23. 236. THE ROLE OF ADJUVANT THERAPY FOLLOWING NEOADJUVANT CHEMORADIOTHERAPY AND ESOPHAGECTOMY IN ESOPHAGEAL CANCER2024Diseases of the Esophagus论文
  24. 240. CACHEXIA INDEX AS A POTENTIAL BIOMARKER FOR SENSITIVITY OF NEOADJUVANT THERAPY AND PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  25. 384. NEOADJUVANT ANLOTINIB COMBINED WITH PENPULIMAB FOR RESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A PROSPECTIVE, SINGLE-ARM, PHASE II TRIAL2024Diseases of the Esophagus论文
  26. 398. DYSPHAGIA OR REGURGITATION AND ITS CORRELATES AMONG UP TO 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS2024Diseases of the Esophagus论文
  27. 424. EFFECT OF GUT MICROBIOTA ON THE RESPONSE TO NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  28. 436. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD2024Diseases of the Esophagus论文
  29. 439. INTEGRATION OF SCRNA-SEQ AND BULK RNA-SEQ TO VALIDATE A PROGNOSTIC ASSOCIATED SIGNATURE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  30. 626. DO CALCIUM CHANNEL BLOCKERS AFFECT CLINICAL OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH HYPERTENSION? A MULTICENTER RETROSPECTIVE STUDY2024Diseases of the Esophagus论文
  31. 798. FEASIBILITY AND EFFICACY OF CISPLATIN, PACLITAXEL AND IMMUNE CHECKPOINT INHIBITORS AS CONVERSION THERAPY FOR LOCOREGIONALLY UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagus论文
  32. A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  33. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  34. Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.2024Journal of Clinical Oncology会议摘要
  35. Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial.2024Journal of Clinical Oncology会议摘要
  36. 14. IMPACTS OF ADDITIONAL CYCLES OF NEOADJUVANT IMMUNOCHEMOTHERAPY ON ESOPHAGECTOMY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagus论文
  37. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncology论文
  38. 186. PROGNOSTIC ROLE OF NODAL SKIP METASTASIS IN THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY2023Diseases of the Esophagus论文
  39. 187. PROGNOSTIC IMPACT OF LYMPH NODE HARVEST FOR PATIENTS WITH NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY2023Diseases of the Esophagus论文
  40. 188. VITAMIN D RECEPTOR INDUCES OXIDATIVE STRESS TO PROMOTE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PROLIFERATION VIA THE P53 SIGNALING PATHWAY2023Diseases of the Esophagus论文
  41. 189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD2023Diseases of the Esophagus论文
  42. 24. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY2023Diseases of the Esophagus论文
  43. 401. THE ADJUVANT IMMUNOTHERAPY COMBINATIONS FOLLOWING ESOPHAGECTOMY FOR RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH NEOADJUVANT THERAPY2023Diseases of the Esophagus论文
  44. 402. LYMPH NODE METASTASIS MAPPING IN T1–2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagus论文
  45. 430. MAPPING OF LYMPH NODE METASTASIS FROM ESCC AFTER NEOADJUVANT TREATMENT: A PROSPECTIVE ANALYSIS FROM A HIGH-VOLUME INSTITUTION IN CHINA2023Diseases of the Esophagus论文
  46. 444. SHOULD T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA BE SUBCLASSIFIED WITH RESPECT TO LYMPH NODE INVOLVEMENT AND SURVIVAL?2023Diseases of the Esophagus论文
  47. 485. MATTHEW EFFECT OF NEOADJUVANT THERAPY IN ESOPHAGEAL CANCER2023Diseases of the Esophagus论文
  48. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  49. P-60 Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial2023Annals of Oncology会议摘要
  50. 137. THE COMPARISON OF SHORT-TERM OUTCOMES BETWEEN NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY AND NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CANCER2022Diseases of the Esophagus论文
  51. 153. APPLICATION OF RAMAN SPECTROSCOPY AND MACHINE LEARNING IN THE CLASSIFICATION OF ESOPHAGEAL SQUAMOUS CARCINOMA2022Diseases of the Esophagus论文
  52. 231. A NOMOGRAM BASED ON BODY MASS INDEX CHANGES TO PREDICT PROGNOSIS AFTER CURATIVE RESECTION OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagus论文
  53. 241. A VALIDATED NOMOGRAM PREDICTING LYMPH NODE METASTASIS OF T2N0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOR CLINICAL DECISION-MAKING2022Diseases of the Esophagus论文
  54. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  55. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figshare数据集
  56. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figshare数据集
  57. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  58. MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway2022Figshare数据集
  59. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  60. 820 EFFICACY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND PRECANCEROUS LESIONS2021Diseases of the Esophagus论文
  61. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集
  62. Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 392 篇,占 2.6%。

牵头论文
392
2021–2025 年
牵头试验
23
任何状态,ClinicalTrials.gov
牵头的开放试验
16
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 606020212022: 777720222023: 717120232024: 868620242025: 89892025

成都有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 23

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07295262

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  2. 正在招募
    Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07295275

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院;另有 2 家列出的医院为研究中心北京、徐州、成都

  3. 正在招募
    Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
    分期
    未注明
    开始
    2026-01
    登记号
    NCT07295340

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  4. 正在招募
    Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07410715

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  5. 正在招募
    PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
    分期
    II期
    开始
    2026-04
    登记号
    NCT07463248

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  6. 正在招募
    A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
    分期
    I/II期
    开始
    2026-02
    登记号
    NCT07482059

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  7. 正在招募
    Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
    分期
    未注明
    开始
    2025-04
    登记号
    NCT06950827

    年龄 18 岁 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

  8. 正在招募
    PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-10
    登记号
    NCT07053072

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:四川大学华西医院成都

  9. 正在招募
    Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-08
    登记号
    NCT07077356

    年龄 18 岁 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

  10. 正在招募
    A Study of GV20-0251 in Advanced or Refractory Solid Tumors
    分期
    I期
    开始
    2025-09
    登记号
    NCT07106827

    年龄 18 岁 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

  11. 正在招募
    PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
    分期
    II期
    开始
    2024-10
    登记号
    NCT06742424

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  12. 正在招募
    Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06219096

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  13. 即将招募
    Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
    分期
    未注明
    开始
    2027-01
    登记号
    NCT07912853

    年龄 18 岁 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

  14. 即将招募
    Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
    分期
    不分期
    开始
    2026-04
    登记号
    NCT07480382

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院成都

  15. 即将招募
    YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2026-07
    登记号
    NCT07580261

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:四川大学华西医院成都

  16. 即将招募
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-12
    登记号
    NCT07866612

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院;另有 8 家列出的医院为研究中心上海、北京、南京、广州、成都、福州、重庆

  17. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  18. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  19. 正在招募
    Phase 2 Study of WGI-0301 for Advanced HCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06309485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心南昌、哈尔滨、成都、杭州、武汉、长沙

  20. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  21. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

  22. 正在招募
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    分期
    I/II期
    开始
    2022-12
    登记号
    NCT05652920

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、成都、杭州、长春、长沙

  23. 即将招募
    Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
    分期
    III期
    开始
    2026-01
    登记号
    NCT07356037

    年龄 18 岁 至 85 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室影像/核医学科普外/肝胆胰外科病理/检验科肿瘤内科
牵头的论文392
  1. Radiofrequency ablation is safe in patients with hepatocellular carcinoma and thrombocytopenia.2026Abdominal radiology (New York)
  2. Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.2026European radiology免费全文
  3. 3D fractal dimension analysis of CT imaging for microvascular invasion prediction in hepatocellular carcinoma.2026European radiology免费全文
  4. Laparoscopic liver resection is superior to open liver resection for hepatocellular carcinoma patients with BCLC stage 0-A hepatocellular carcinoma and portal hypertension.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.2026International journal of surgery (London, England)
  6. Ultrasound shear wave viscoelastic imaging combined with shear wave elastography for characterization of focal liver lesions.2026Journal of biomechanics
  7. Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.2026Journal of magnetic resonance imaging : JMRI免费全文
  8. Multicenter study on right Glissonean pedicle management in laparoscopic right hepatectomy: main trunk vs. sectoral pedicle transection approaches.2026Surgical endoscopy
  9. Laparoscopic versus open hepatectomy in hepatocellular carcinoma patients with high-risk pathological features: a multicenter propensity score-matched study.2026Surgical endoscopy
  10. Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis.2025Academic radiology
  11. Perfluorohexane nanodroplet-assisted mechanical high intensity focused ultrasound cavitation: A strategy for hepatocellular carcinoma treatment.2025Acta biomaterialia
  12. Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study.2025Annals of surgical oncology
  13. Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.2025Annals of surgical oncology
  14. Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.2025BMC cancer免费全文
  15. Low preoperative serum creatinine levels are associated with poor prognosis in patients with hepatocellular carcinoma after liver resection: a multicenter study.2025BMC gastroenterology免费全文
  16. Nomogram for predicting early cancer-related death due to recurrence after liver resection in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C: a multicenter study.2025BMC gastroenterology免费全文
  17. Discovery of targeting USP10-mediated proline metabolism arrangement to inhibit hepatocellular carcinoma progression.2025Biochemical pharmacology
  18. Histone lactylation facilitates MCM7 expression to maintain stemness and radio-resistance in hepatocellular carcinoma.2025Biochemical pharmacology
  19. Utilizing liquid-liquid biopolymer regulators to predict the prognosis and drug sensitivity of hepatocellular carcinoma.2025Biology direct免费全文
  20. Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.2025Bioscience trends
  21. Textbook outcome and survival following laparoscopic versus open right hemihepatectomy for hepatocellular carcinoma: A propensity score-matched study.2025Bioscience trends
  22. Performance of simultaneous multislice diffusion-weighted imaging using monoexponential, intravoxel incoherent motion, and diffusion kurtosis models: assessment of microvascular invasion and histologic grade in hepatocellular carcinoma.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  23. Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.2025Cancer medicine免费全文
  24. Preoperative Hepatic Augmentation Versus Transarterial Chemoembolization for Hepatocellular Carcinoma With Insufficient Remnant Liver Volume: A Systematic Review and Meta-Analysis.2025Cancer medicine免费全文
  25. Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma.2025Cell biology and toxicology免费全文
  26. Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease.2025Cell reports
  27. circCEP70 encoded protein inhibits the progression of hepatocellular carcinoma.2025Cellular and molecular life sciences : CMLS免费全文
  28. EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  29. Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels.2025Clinical and translational gastroenterology免费全文
  30. Acute cutaneous adverse drug reactions in hepatocellular carcinoma patients undergoing combined targeted and immunotherapy: unraveling the impact of dosage and interval.2025Cutaneous and ocular toxicology
  31. Long-Term Outcome of Repeat Resection versus Radiofrequency Ablation for Intrahepatic Recurrence after Curative Resection of Hepatocellular Carcinoma Initially within Barcelona Clinic Liver Cancer Staging System 0-A Stages: A Multicenter St2025Digestive diseases (Basel, Switzerland)
  32. Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.2025European journal of medical researchRCT免费全文
  33. Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.2025European journal of radiology
  34. Validation of the Iwate scoring system for the stratification of laparoscopic liver resections: An international multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  35. MRI-based prediction of microvascular invasion/high tumor grade and adjuvant therapy benefit for solitary HCC ≤ 5 cm: a multicenter cohort study.2025European radiology免费全文
  36. MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.2025European radiology免费全文
  37. Deep learning-based 3D quantitative total tumor burden predicts early recurrence of BCLC A and B HCC after resection.2025European radiology免费全文
  38. Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.2025European radiology免费全文
  39. Preoperative prediction of early recurrence in hepatocellular carcinoma using simultaneous multislice diffusion kurtosis imaging.2025European radiology
  40. ANK3 Is Regulated by Recursive Splicing and Inhibits Hepatocellular Carcinoma Metastasis by Inhibiting E-Cadherin Protein Degradation.2025Frontiers in bioscience (Landmark edition)
  41. The role of bile acid metabolism-related genes in prognosis assessment of hepatocellular carcinoma and identification of NPC1 as a biomarker.2025Frontiers in endocrinology免费全文
  42. Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.2025Frontiers in immunology免费全文
  43. Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor.2025Frontiers in immunology免费全文
  44. Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy.2025Frontiers in immunology免费全文
  45. Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC.2025Frontiers in immunology免费全文
  46. The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma.2025Frontiers in immunology免费全文
  47. Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.2025Frontiers in public health免费全文
  48. PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.2025Future oncology (London, England)免费全文
  49. Multisite long-read sequencing reveals the early contributions of somatic structural variations to HBV-related hepatocellular carcinoma tumorigenesis.2025Genome research免费全文
  50. Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth by inhibiting Hippo signaling in HCC.2025Hepatology (Baltimore, Md.)
  51. Identification of Core gene expression alterations regulated by gut microbiota in tumor progression and immunotherapy resistance through integrative pan-cancer analysis.2025International journal of biological macromolecules
  52. The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma.2025International journal of biological sciences免费全文
  53. Fractal analysis based on Gd-EOB-DTPA-enhanced MRI for prediction of vessels that encapsulate tumor clusters in patients with hepatocellular carcinoma.2025International journal of surgery (London, England)
  54. Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.2025International journal of surgery (London, England)免费全文
  55. Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma.2025International journal of surgery (London, England)免费全文
  56. Integrative analysis of senescence-related genes identifies robust prognostic clusters with distinct features in hepatocellular carcinoma.2025Journal of advanced research免费全文
  57. DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway.2025Journal of cellular and molecular medicine免费全文
  58. Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.2025Journal of gastroenterology and hepatology
  59. CD44 and mitochondria dual-targeted polydopamine nanoplatform for combined chemotherapy, photothermal ablation, and immunogenic cell death induction in liver cancer.2025Journal of materials chemistry. B
  60. Wild-Type and rtA181T/sW172* Mutant Strains of Hepatitis B Virus Drive Hepatocarcinogenesis via Distinct GRP78-Mediated ER Stress Pathways.2025Journal of medical virology
  61. A Soluble Triantennary N-Acetylgalactosamine Camptothecin Prodrug for Hepatocellular Carcinoma-Targeted Therapy.2025Journal of medicinal chemistry
  62. MMAE-Based Peptide-Drug Conjugates Targeting GPC3 for Precision Chemoradiotherapy in Hepatocellular Carcinoma.2025Journal of medicinal chemistry
  63. Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.2025Journal of medicinal chemistry
  64. Synergistic Ultrasound-Activable Artificial Enzyme and Precision Gene Therapy to Suppress Redox Homeostasis and Malignant Phenotypes for Controllably Combating Hepatocellular Carcinoma.2025Journal of the American Chemical Society
  65. A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.2025Langenbeck's archives of surgery免费全文
  66. Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.2025Langenbeck's archives of surgery免费全文
  67. MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.2025Liver international : official journal of the International Association for the Study of the Liver免费全文
  68. Unveiling causal links between serum amino acid levels and risk of hepatobiliary neoplasms by Mendelian randomization study.2025Medicine免费全文
  69. Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects.2025Molecular cancer therapeutics
  70. FBP1 controls liver cancer evolution from senescent MASH hepatocytes.2025Nature免费全文
  71. The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment.2025Nature communications免费全文
  72. Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling.2025Oncogene
  73. RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.2025Oncogene
  74. CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91/HLA-A *0201 exhibit potent activity against HBV-HCC.2025Oncoimmunology免费全文
  75. Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.2025Oncology research免费全文
  76. Hypoxia-induced exosomal lncRNA-PVT1 as a biomarker and mediator of EMT in hepatocellular carcinoma.2025Oncology research免费全文
  77. EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy.2025Oncology research免费全文
  78. Progressed Atrioventricular Block in Immune Checkpoint Inhibitor Induced Myocarditis: A Case Report.2025Pacing and clinical electrophysiology : PACE
  79. Identification and functional analysis of five hub lncRNAs associated with oncogenesis of Hepatocellular Carcinoma.2025PloS one免费全文
  80. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis.2025PloS one免费全文
  81. Histone lactylation drives liver cancer metastasis by facilitating NSF1-mediated ferroptosis resistance after microwave ablation.2025Redox biology免费全文
  82. Comprehensive multi-phase 3D contrast-enhanced CT imaging for primary liver cancer.2025Scientific data免费全文
  83. Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma.2025Scientific reports免费全文
  84. Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors.2025Scientific reports免费全文
  85. TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis.2025Scientific reports免费全文
  86. KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma.2025Signal transduction and targeted therapy免费全文
  87. Ultrasensitive Electrochemical Screening of Circulating Tumor Cells Over Single-Atom Nanozyme Integrated 3D Nanoarray.2025Small (Weinheim an der Bergstrasse, Germany)
  88. Indocyanine green fluorescence staining-guided laparoscopic posterosuperior segmentectomy: A multicenter retrospective cohort study.2025Surgical endoscopy
  89. Indocyanine green fluorescence imaging (ICG-FI) in difficult laparoscopic hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matched analysis.2025Surgical endoscopy免费全文
  90. Comparison of textbook outcomes between laparoscopic and open liver resection for patients with hepatocellular carcinoma: a multicenter study.2025Surgical endoscopy
  91. Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial.2025Trials免费全文
  92. Short- and long-term outcomes following laparoscopic liver resection for hepatocellular carcinoma combined with type I/II portal vein tumor thrombus.2025Updates in surgery
  93. Three-dimensional location approach with silk thread guided hepatectomy for liver tumor.2025World journal of gastroenterology免费全文
  94. Current status of drug therapy for chronic hepatitis B.2025World journal of gastroenterology免费全文
  95. Intraoperative Blood Transfusion has a Distinct Impact on the Long-Term Prognosis of Hepatocellular Carcinoma Patients With Different Alpha-Fetoprotein-Tumor Burden Scores After Liver Resection: A Large-Scale Multicenter Study.2025World journal of surgery
  96. Therapeutic efficacy of hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a propensity score matching study.2025World journal of surgical oncology免费全文
  97. Predictive value of combined Albumin-Globulin score and psoas muscle index for postoperative prognosis in combined hepatocellular carcinoma and cholangiocarcinoma.2025World journal of surgical oncology免费全文
  98. Short- and medium-term impacts of unplanned intraoperative conversion during laparoscopic liver resection for hepatocellular carcinoma patients: a propensity score-matched study.2025World journal of surgical oncology免费全文
  99. Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade.2024ACS applied materials & interfaces
  100. Quantitative diffusion weighted imaging in patients with hepatocellular carcinoma: effects of simultaneous multi-slice acceleration and gadoxetic acid administration.2024Abdominal radiology (New York)
  101. Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.2024Abdominal radiology (New York)
  102. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma.2024Abdominal radiology (New York)
  103. The Impact of Imaging-Diagnosed Sarcopenia on Long-term Prognosis After Curative Resection for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Academic radiology
  104. Oxidative Stress Promotes Liver Cancer Metastasis via RNF25-Mediated E-Cadherin Protein Degradation.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  105. Dual Enzyme-Locked Activation Reporter for Accurate Liver Cancer Surveillance.2024Analytical chemistry
  106. Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCs.2024Analytical chemistry
  107. Pure Laparoscopic Anatomic Resection of Liver Segment 4 with Middle Hepatic Vein Involvement Using Indocyanine Green Fluorescence Staining.2024Annals of surgical oncology
  108. Laparoscopic Anatomical Cranial Sub-segmentectomy of Segment VII (S7) with Super-Selective Intra-arterial Nano-ICG Positive Staining-Guided Trans-Parenchymal Approach.2024Annals of surgical oncology
  109. Laparoscopic Anatomic Bi-segmentectomy (S5 and S6) Using Takasaki's Approach and Indocyanine Green Fluorescence Navigation.2024Annals of surgical oncology
  110. Novel CAR-T cells targeting TRKB for the treatment of solid cancer.2024Apoptosis : an international journal on programmed cell death
  111. Transhepatic arterial approaches for ICG injection to guide laparoscopic anatomical hepatectomy: A case series study.2024Asian journal of surgery
  112. Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.2024Asian journal of surgery
  113. Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B.2024Asian journal of surgery
  114. Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review.2024Asian journal of surgery
  115. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma.2024BMC cancer免费全文
  116. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.2024BMC cancer免费全文
  117. Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.2024BMC cancer免费全文
  118. Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.2024BMC cancer免费全文
  119. Identification of CD8+ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing.2024BMC cancer免费全文
  120. Evaluating the diagnostic accuracy of heat shock proteins and their combination with Alpha-Fetoprotein in the detection of hepatocellular carcinoma: a meta-analysis.2024BMC gastroenterology免费全文
  121. The effectiveness of problem-based learning and case-based learning teaching methods in clinical practical teaching in TACE treatment for hepatocellular carcinoma in China: a bayesian network meta-analysis.2024BMC medical education免费全文
  122. Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.2024BMJ open免费全文
  123. Inhibiting Pink1/Parkin-mediated mitophagy enhances the anticancer effects of quercetin in hepatocellular carcinomaf.2024Biochemical and biophysical research communications
  124. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.2024Biochemical pharmacology
  125. UBAP2 contributes to radioresistance by enhancing homologous recombination through SLC27A5 ubiquitination in hepatocellular carcinoma.2024Biochimica et biophysica acta. Molecular basis of disease
  126. A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment.2024Biomaterials
  127. The role of cholesterol-modified prognostic nutritional index in nutritional status assessment and predicting survival after liver resection for hepatocellular carcinoma.2024Bioscience trends
  128. PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.2024Cancer medicine免费全文
  129. Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.2024Cancer medicine免费全文
  130. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.2024Cancer medicine免费全文
  131. NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.2024Cancer science免费全文
  132. SUMOylation of annexin A6 retards cell migration and tumor growth by suppressing RHOU/AKT1-involved EMT in hepatocellular carcinoma.2024Cell communication and signaling : CCS免费全文
  133. Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  134. Hyperpolarized 13 C MRI in hepatocellular carcinoma: Unmet questions during clinical translation.2024Chinese medical journal免费全文
  135. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.2024Clinics and research in hepatology and gastroenterology
  136. A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.2024Computers in biology and medicine
  137. Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma.2024European journal of medicinal chemistry
  138. Extracellular contrast agent-enhanced MRI is as effective as gadoxetate disodium-enhanced MRI for predicting microvascular invasion in HCC.2024European journal of radiology
  139. Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  140. Tumor burden score is superior to primary liver cancer stages in predicting prognosis for patients with combined hepatocellular-cholangiocarcinoma after surgery: A multi-center study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  141. Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma.2024European radiology免费全文
  142. Apparent diffusion coefficient and tissue stiffness are associated with different tumor microenvironment features of hepatocellular carcinoma.2024European radiology免费全文
  143. miRNAs in patients with alcoholic liver disease: a systematic review and meta-analysis.2024Expert review of gastroenterology & hepatology
  144. Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma.2024Free radical biology & medicine
  145. Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.2024Frontiers in immunology免费全文
  146. Extrachromosomal circular MiR-17-92 amplicon promotes HCC.2024Hepatology (Baltimore, Md.)
  147. Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.2024Hepatology (Baltimore, Md.)
  148. Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?2024Hepatology (Baltimore, Md.)
  149. BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma.2024International journal of molecular sciences免费全文
  150. NIR-II-Absorbing NDI Polymer with Superior Penetration Depth for Enhanced Photothermal Therapy Efficiency of Hepatocellular Carcinoma.2024International journal of nanomedicine免费全文
  151. Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study.2024International journal of surgery (London, England)免费全文
  152. A commentary on 'Global research status and frontiers on autophagy in hepatocellular carcinoma: a comprehensive bibliometric and visualized analysis'.2024International journal of surgery (London, England)免费全文
  153. A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'.2024International journal of surgery (London, England)免费全文
  154. A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'.2024International journal of surgery (London, England)免费全文
  155. Inhibition of NPC1 suppresses cell proliferation and β-catenin signaling activation of liver cancer.2024Journal of cancer research and clinical oncology免费全文
  156. A flexible deep learning framework for liver tumor diagnosis using variable multi-phase contrast-enhanced CT scans.2024Journal of cancer research and clinical oncology免费全文
  157. Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  158. Integrated Single-Cell and Spatial Transcriptome Reveal Metabolic Gene SLC16A3 as a Key Regulator of Immune Suppression in Hepatocellular Carcinoma.2024Journal of cellular and molecular medicine免费全文
  159. Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma.2024Journal of extracellular vesicles免费全文
  160. RNA-binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152.2024Journal of gastroenterology and hepatology免费全文
  161. Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.2024Journal of gastroenterology and hepatology
  162. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.2024Journal of magnetic resonance imaging : JMRI
  163. Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.2024Journal of medicinal chemistry
  164. Treatments for Early Hepatocellular Carcinoma: Resection or Ablation-How to Make a Decision.2024Journal of the American College of Radiology : JACR
  165. Deep learning-based compressed SENSE improved diffusion-weighted image quality and liver cancer detection: A prospective study.2024Magnetic resonance imaging
  166. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies.2024Metabolism: clinical and experimental
  167. Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC.2024Molecular medicine reports免费全文
  168. Focal liver lesion diagnosis with deep learning and multistage CT imaging.2024Nature communications免费全文
  169. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.2024Nature communications免费全文
  170. METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.2024Oncogene
  171. Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.2024Oncology research免费全文
  172. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  173. Comprehensive analysis of bioinformatics and system biology reveals the association between Girdin and hepatocellular carcinoma.2024PloS one免费全文
  174. Prognostic Implications of MRI-assessed Intratumoral Fat in Hepatocellular Carcinoma: An Asian and European Cohort Study.2024Radiology
  175. LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.2024Radiology
  176. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.2024Scientific reports免费全文
  177. Hypoxia-induced nuclear localization of ubiquinol-cytochrome-c reductase complex assembly factor 3 (UQCC3) in hepatocellular carcinoma.2024Signal transduction and targeted therapy免费全文
  178. Use of indocyanine green-human serum albumin complexes in fluorescence image-guided laparoscopic anatomical liver resection: a case series study (with video).2024Surgical endoscopy免费全文
  179. Impact of metabolic dysfunction-associated fatty liver disease on the outcomes following laparoscopic hepatectomy for hepatocellular carcinoma.2024Surgical endoscopy
  180. Caudo-dorsal approach combined with the occlusion of right hepatic vein and Pringle maneuver in laparoscopic anatomical resection of segment 7.2024Surgical endoscopy
  181. Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.2024The British journal of surgery免费全文
  182. Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.2024Trials免费全文
  183. Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.2024World journal of gastroenterology免费全文
  184. Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.2024World journal of surgical oncology免费全文
  185. Laparoscopic Anatomical Resection of Paracaval Portion of Caudate Lobe and Segment 8 for HCC in an HCV-Related Cirrhotic Patient.2023Annals of surgical oncology
  186. Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: Report of two cases.2023Asian journal of surgery
  187. Gamma-glutamyl transpeptidase to albumin ratio holds a prognostic significance after hepatectomy in patients with hepatocellular carcinoma and liver cirrhosis.2023Asian journal of surgery
  188. Efficacy of LR-5 and LR-4/5 by Liver Imaging Reporting and Data System (MRI) for hepatocellular carcinoma: A meta-analysis.2023Asian journal of surgery
  189. Rupture and hemorrhage of a large primary liver tumor in caudate lobe.2023Asian journal of surgery
  190. Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2.2023BMC cancer免费全文
  191. Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.2023BMC cancer免费全文
  192. A new method for predicting the microvascular invasion status of hepatocellular carcinoma through neural network analysis.2023BMC surgery免费全文
  193. The prognostic nutritional index and tumor pathological characteristics predict the prognosis of elderly patients with early-stage hepatocellular carcinoma after surgery.2023Bioscience trends
  194. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.2023Bioscience trends
  195. Incidence and trends of hepatic cancer among children and adolescents in the United States from 2000 to 2017: Evidence from the Surveillance, Epidemiology, and End Results registry data.2023Cancer causes & control : CCC
  196. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.2023Cancer medicine免费全文
  197. Insurance status impacts survival of hepatocellular carcinoma patients after liver resection.2023Cancer medicine免费全文
  198. Risk factors of postoperative bile leakage after liver resection: A systematic review and meta-analysis.2023Cancer medicine免费全文
  199. Repeat hepatic resection combined with intraoperative radiofrequency ablation versus repeat hepatic resection alone for recurrent and multiple hepatocellular carcinoma patients meeting the Barcelona Clinic Liver Cancer stage A: A propensity2023Cancer medicine免费全文
  200. Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.2023Cell death & disease免费全文
  201. HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.2023Cellular and molecular gastroenterology and hepatology免费全文
  202. DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  203. Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.2023Chinese medical journal免费全文
  204. Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma.2023Chinese medical journal免费全文
  205. Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.2023Clinical nuclear medicine
  206. The value of MRI in predicting hepatocellular carcinoma with cytokeratin 19 expression: a systematic review and meta-analysis.2023Clinical radiology
  207. Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.2023Computers in biology and medicine
  208. EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.2023Digestive diseases (Basel, Switzerland)
  209. TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.2023Digestive diseases and sciences免费全文
  210. Dysregulated cholesterol regulatory genes in hepatocellular carcinoma.2023European journal of medical research免费全文
  211. Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.2023European journal of medicinal chemistry
  212. Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging免费全文
  213. Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy.2023European journal of radiology
  214. Nomogram to predict liver surgery-specific complications for hepatocellular carcinoma: A multicenter study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  215. Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.2023European radiology免费全文
  216. Intravoxel incoherent motion diffusion weighted imaging for preoperative evaluation of liver regeneration after hepatectomy in hepatocellular carcinoma.2023European radiology
  217. Quality of radiomics for predicting microvascular invasion in hepatocellular carcinoma: a systematic review.2023European radiology
  218. Ferroptosis signaling promotes the release of misfolded proteins via exosomes to rescue ER stress in hepatocellular carcinoma.2023Free radical biology & medicine
  219. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  220. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk.2023Frontiers in immunology免费全文
  221. Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression.2023Frontiers in immunology免费全文
  222. The appropriate method of hepatectomy for hepatocellular carcinoma within University of California San Francisco (UCSF) criteria through neural network analysis.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  223. Clinical prognosis and related molecular features of hepatitis B-associated adolescent and young adult hepatocellular carcinoma.2023Human genomics免费全文
  224. HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.2023Immunological investigations
  225. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).2023International journal of molecular sciences免费全文
  226. Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  227. USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation.2023International journal of oncology免费全文
  228. Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial.2023International journal of surgery (London, England)RCT免费全文
  229. Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma.2023Journal of experimental & clinical cancer research : CR免费全文
  230. Parenchymal Sparing Laparoscopic Segmentectomy III and IV with Indocyanine Green Fluorescence Negative Stain Method Using Glisson Pedicle Approach.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  231. Meta-analysis of Prognostic Factors for Overall Survival Among Resected Patients with Spontaneous Ruptured Hepatocellular Carcinoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  232. The current role of radiofrequency ablation in the treatment of intrahepatic recurrent hepatocellular carcinoma.2023Journal of surgical oncology
  233. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.2023Laboratory investigation; a journal of technical methods and pathology
  234. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.2023Langenbeck's archives of surgeryRCT
  235. Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma.2023Liver international : official journal of the International Association for the Study of the Liver
  236. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.2023Molecular cancer免费全文
  237. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.2023Nature communications免费全文
  238. Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis.2023Panminerva medica
  239. Hollow MnO2-Based Nanoprobes for Enhanced Photothermal/Photodynamic /Chemodynamic Co-Therapy of Hepatocellular Carcinoma.2023Pharmaceutical research
  240. Upper-critical solution temperature (UCST) polymer functionalized nanomedicine for controlled drug release and hypoxia alleviation in hepatocellular carcinoma therapy.2023PloS one免费全文
  241. Universal Liver Imaging Lexicon: Imaging Atlas for Research and Clinical Practice.2023Radiographics : a review publication of the Radiological Society of North America, Inc
  242. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.2023Radiology
  243. Development of a Model including MRI Features for Predicting Advanced-stage Recurrence of Hepatocellular Carcinoma after Liver Resection.2023Radiology
  244. Hepatocellular Carcinoma: It Is Time to Focus on Prognosis.2023Radiology免费全文
  245. Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives.2023Radiology
  246. VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC.2023Radiology
  247. Prognostic nomograms for HBV-related BCLC 0-a stage hepatocellular carcinoma incorporating aspartate aminotransferase to albumin ratio.2023Scandinavian journal of gastroenterology
  248. Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant.2023Signal transduction and targeted therapy免费全文
  249. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma.2023The British journal of surgery
  250. Hierarchically tumor-activated nanoCRISPR-Cas13a facilitates efficient microRNA disruption for multi-pathway-mediated tumor suppression.2023Theranostics免费全文
  251. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.2023Trials免费全文
  252. Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial.2023Trials免费全文
  253. Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a systematic review of propensity score-matched studies.2023Updates in surgery免费全文
  254. Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?2023Updates in surgery免费全文
  255. Hepatitis B Virus X Protein Modulates p90 Ribosomal S6 Kinase 2 by ERK to Promote Growth of Hepatoma Cells.2023Viruses免费全文
  256. Simultaneous Homogeneous Fluorescence Detection of AFP and GPC3 in Hepatocellular Carcinoma Clinical Samples Assisted by Enzyme-Free Catalytic Hairpin Assembly.2022ACS applied materials & interfaces
  257. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma.2022ACS applied materials & interfaces
  258. Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.2022Annals of surgical oncology
  259. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas.2022Annals of surgical oncology
  260. ASO Author Reflections: How to Choose the Optimal Strategy to Treat Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas?2022Annals of surgical oncology
  261. ASO Author Reflections: Pure Laparoscopic Right Upper Transversal Hepatectomy.2022Annals of surgical oncology
  262. Pure Laparoscopic Right Upper Transversal Hepatectomy.2022Annals of surgical oncology
  263. ASO Author Reflections: How to Choose the Optimal Surgical Strategy to Finish Laparoscopic Anatomical Hepatectomy for a Solitary HCC in the Left Lobe?2022Annals of surgical oncology
  264. Laparoscopic Segmentectomy IV Using Hepatic Round Ligament Approach Combined with Fluorescent Negative Staining Method.2022Annals of surgical oncology
  265. Primary hepatic gastrointestinal stromal tumor: A case series.2022Asian journal of surgery
  266. Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controll2022Asian journal of surgeryRCT
  267. Novel postoperative nomograms for predicting individual prognoses of hepatitis B-related hepatocellular carcinoma with cirrhosis.2022BMC surgeryRCT免费全文
  268. Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study.2022BMC surgery免费全文
  269. Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.2022BMC surgery免费全文
  270. The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.2022BMC surgery免费全文
  271. Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis.2022BMC surgery免费全文
  272. Liver transplantation in China: Achievements over the past 30 years and prospects for the future.2022Bioscience trends
  273. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.2022Bioscience trends
  274. Use of chemotherapy to treat hepatocellular carcinoma.2022Bioscience trends
  275. A detailed multi-omics analysis of GNB2 gene in human cancers.2022Brazilian journal of biology = Revista brasleira de biologia
  276. The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition.2022Cancer letters
  277. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.2022Cancer medicine免费全文
  278. Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis.2022Carcinogenesis
  279. New classification-oriented laparoscopic anatomical hepatectomy strategy for hepatocellular carcinoma invading two or more (sub)segments in the left lobe.2022Chinese medical journal免费全文
  280. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.2022Chinese medical journal免费全文
  281. Conversion resection for patients with hepatocellular carcinoma and inferior vena cava tumor thrombus: a consecutive case series.2022Chinese medical journal免费全文
  282. Safety of elective hepatectomy performed on weekend for patients with hepatocellular carcinoma.2022Chinese medical journal免费全文
  283. Upregulation of SERPINE2 Results in Poor Prognosis of Hepatoblastoma via Promoting Invasion Abilities.2022Disease markers免费全文
  284. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.2022EMBO molecular medicine免费全文
  285. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease.2022European journal of clinical pharmacology
  286. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.2022European journal of radiology
  287. Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  288. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  289. The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  290. Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.2022European radiology免费全文
  291. A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients.2022Frontiers in immunology免费全文
  292. Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.2022Frontiers in immunology免费全文
  293. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.2022Frontiers in immunology免费全文
  294. A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  295. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.2022Frontiers in immunology免费全文
  296. Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  297. Overexpression of transcription factor 3 drives hepatocarcinoma development by enhancing cell proliferation via activating Wnt signaling pathway.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  298. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.2022Hepatology (Baltimore, Md.)免费全文
  299. Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics.2022Immunologic research
  300. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.2022International immunopharmacology
  301. The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.2022International journal of cancer免费全文
  302. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.2022International journal of molecular sciences免费全文
  303. Hemihepatic versus total hepatic inflow occlusion for laparoscopic hepatectomy: A randomized controlled trial.2022International journal of surgery (London, England)RCT
  304. Benefit of a Live Donor for Patients With Hepatocellular Carcinoma on the Waiting List.2022JAMA surgery
  305. Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.2022Journal of cancer research and clinical oncology免费全文
  306. OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells.2022Journal of clinical laboratory analysis免费全文
  307. A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy.2022Journal of colloid and interface science
  308. LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.2022Journal of experimental & clinical cancer research : CR免费全文
  309. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.2022Journal of hepatology免费全文
  310. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.2022Journal of hepatology
  311. Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma.2022Journal of immunology research免费全文
  312. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.2022Journal of magnetic resonance imaging : JMRI
  313. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.2022Journal of magnetic resonance imaging : JMRI
  314. The Value of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  315. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions.2022Liver international : official journal of the International Association for the Study of the Liver
  316. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI.2022Liver international : official journal of the International Association for the Study of the Liver免费全文
  317. Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling.2022Molecular cancer免费全文
  318. UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.2022Oncogene
  319. Transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis.2022Oncology research免费全文
  320. A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease Staging, and Prognoses in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  321. Uvangoletin, extracted from Sarcandra glabra, exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  322. HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.2022Redox biology免费全文
  323. A randomized controlled trial of effect of 15- or 25-minute intermittent Pringle maneuver on hepatectomy for hepatocellular carcinoma.2022SurgeryRCT
  324. Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center.2022Surgical endoscopy免费全文
  325. Laparoscopic anatomic bi-segmentectomy (S3 and S4b) using the Glisson's pedicle-first and intrahepatic anatomic markers approach.2022Surgical endoscopy
  326. Trocar layouts in laparoscopic liver surgery.2022Surgical endoscopy
  327. Is the anterior approach suitable for laparoscopic right hemihepatectomy in patients with large HCC (5-10 cm)? A propensity score analysis.2022Surgical endoscopy
  328. Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid.2022The Journal of clinical endocrinology and metabolism
  329. Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.2022Updates in surgery
  330. Four-year experience with more than 1000 cases of total laparoscopic liver resection in a single center.2022World journal of gastroenterology免费全文
  331. Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.2022World journal of gastroenterology免费全文
  332. Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  333. Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.2021Aging免费全文
  334. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.2021Aging免费全文
  335. The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study.2021Aging免费全文
  336. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.2021Annals of palliative medicine
  337. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages.2021Annals of surgical oncology
  338. The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.2021Anti-cancer drugs
  339. The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis.2021Asia-Pacific journal of clinical oncology
  340. 18-FDG PET/CT provides solid evidence of microvascular invasion and is correlated with prognosis in patients with hepatocellular carcinoma.2021Asian journal of surgery
  341. Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis.2021Asian journal of surgery
  342. Comparison of preoperative two-dimensional shear wave elastography, indocyanine green clearance test and biomarkers for post hepatectomy liver failure prediction in patients with hepatocellular carcinoma.2021BMC gastroenterology免费全文
  343. Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study.2021BMC surgery免费全文
  344. Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.2021Bioengineered免费全文
  345. The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus.2021Bioscience trends
  346. Combination of albumin-bilirubin grade and clinically significant portal hypertension predicts the prognosis of patients with hepatocellular carcinoma after liver resection.2021Bioscience trends
  347. Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma.2021British journal of pharmacology
  348. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.2021Cancer medicine免费全文
  349. Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.2021Cancer science免费全文
  350. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.2021Cell death & disease免费全文
  351. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.2021Cell death & disease免费全文
  352. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.2021Cellular and molecular gastroenterology and hepatology免费全文
  353. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  354. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.2021Chinese medical journal免费全文
  355. MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.2021Clinical and translational medicine免费全文
  356. The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis.2021Clinical imaging
  357. HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway.2021Clinical immunology (Orlando, Fla.)
  358. Prediction of Remnant Liver Regeneration after Right Hepatectomy in Patients with Hepatocellular Carcinoma Using Preoperative CT Texture Analysis and Clinical Features.2021Contrast media & molecular imaging免费全文
  359. Laparoscopic liver resection for hepatocellular carcinoma presents less respiratory complications compared with open procedure: A propensity score analysis in the elderly.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  360. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging.2021European radiology
  361. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?2021European radiology
  362. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.2021European radiology
  363. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.2021European radiology免费全文
  364. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.2021Expert opinion on therapeutic targets免费全文
  365. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  366. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  367. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.2021Hepatology (Baltimore, Md.)免费全文
  368. Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB.2021Hepatology (Baltimore, Md.)
  369. Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.2021International immunopharmacology
  370. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.2021International journal of medical sciences免费全文
  371. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF)2021Journal of cancer research and clinical oncology免费全文
  372. Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma.2021Journal of cellular and molecular medicine免费全文
  373. The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  374. Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.2021Journal of hematology & oncology免费全文
  375. Baseline HBV-DNA load plus AST/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: A multicentre study.2021Journal of viral hepatitis
  376. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.2021Liver international : official journal of the International Association for the Study of the LiverRCT
  377. Donafenib treatment for hepatocellular carcinoma: A case report.2021Medicine免费全文
  378. Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.2021Medicine免费全文
  379. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.2021Medicine免费全文
  380. Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy.2021Medicine免费全文
  381. Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis.2021Medicine免费全文
  382. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients.2021Scientific reports免费全文
  383. Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma.2021Scientific reports免费全文
  384. Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade.2021Scientific reports免费全文
  385. Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.2021Surgical oncology
  386. Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial.2021The oncologist免费全文
  387. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR.2021Theranostics免费全文
  388. Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases.2021Tumori
  389. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis.2021Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  390. Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.2021World journal of gastroenterologyRCT免费全文
  391. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.2021World journal of surgical oncology免费全文
  392. The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis.2021World journal of surgical oncology免费全文
中文论文(未计入)8
  1. [Surgical management of multinodular hepatocellular carcinoma: controversies,opportunities,and challenges].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. Expression of signal recognition particle 14 in hepatocellular carcinoma and its relationship with disease progression and patient survival.2024Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences免费全文
  3. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].2023Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  4. [Evaluation of clinical safety and diagnostic efficacy of domestic liver-specific magnetic resonance contrast agent (gadoxetate disodium)].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [Prognosis prediction model for hepatocellular carcinoma based on autophagy related genes].2022Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi免费全文
  6. [Fucoidan-Modified Phase-Transitional Contrast Agent for Ultrasound Imaging and Targeting of Hepatoma Cells].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  7. [Mechanism of miRNA-3679 Inhibiting Downstream ZADH2-Target Genes to Promote Hepatocellular Carcinoma Cell Proliferation].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  8. [Impact of treatment compliance in chronic hepatitis B].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)65
  1. Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.即将招募NCT07912853牵头方2027-01 启动
  2. YMN-A02 for Advanced Primary Hepatocellular Carcinoma.即将招募NCT07580261牵头方I期2026-07 启动
  3. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma即将招募NCT07866612牵头方不分期2026-12 启动
  4. A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma正在招募NCT07482059牵头方I/II期2026-02 启动
  5. NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC正在招募NCT07295262牵头方早期I期2026-01 启动
  6. Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma正在招募NCT07410715牵头方2026-03 启动
  7. Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection正在招募NCT07295275牵头方2026-03 启动
  8. Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection正在招募NCT07295340牵头方2026-01 启动
  9. PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.正在招募NCT07053072牵头方I期2025-10 启动
  10. A Study of GV20-0251 in Advanced or Refractory Solid Tumors正在招募NCT07106827牵头方I期2025-09 启动
  11. Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma正在招募NCT06950827牵头方2025-04 启动
  12. Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma正在招募NCT07077356牵头方I期2025-08 启动
  13. PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC正在招募NCT06742424牵头方II期2024-10 启动
  14. Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection正在招募NCT06219096牵头方不分期2023-12 启动
  15. Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT状态不明NCT06664996牵头方II期2024-10 启动
  16. Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma状态不明NCT05738447牵头方I期2023-02 启动
  17. Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC状态不明NCT05544253牵头方II/III期2022-10 启动
  18. Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC状态不明NCT04547452牵头方II期2020-07 启动
  19. Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy已完成NCT04295330牵头方不分期2020-02 启动
  20. RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection状态不明NCT04032860牵头方IV期2017-07 启动
  21. Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC即将招募NCT07480382牵头方(推断)不分期2026-04 启动
  22. PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy正在招募NCT07463248牵头方(推断)II期2026-04 启动
  23. The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC状态不明NCT05042336牵头方(推断)I/II期2021-09 启动
  24. Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma即将招募NCT07356037研究中心III期2026-01 启动
  25. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  26. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  27. Phase 2 Study of WGI-0301 for Advanced HCC正在招募NCT06309485研究中心II期2024-07 启动
  28. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  29. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  30. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC正在招募NCT05652920研究中心I/II期2022-12 启动
  31. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  32. Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma状态不明NCT06558227研究中心II期2024-10 启动
  33. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动
  34. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  35. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  36. Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients进行中,不再招募NCT05377034研究中心II期2022-10 启动
  37. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  38. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  39. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)状态不明NCT04741165研究中心II期2021-01 启动
  40. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  41. A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma状态不明NCT05603039研究中心I/II期2021-07 启动
  42. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  43. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  44. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  45. Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC状态不明NCT04241523研究中心II期2020-01 启动
  46. The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma已完成NCT04997850研究中心I/II期2020-10 启动
  47. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma已完成NCT04401800研究中心II期2020-09 启动
  48. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  49. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  50. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  51. Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma状态不明NCT04227808研究中心II期2019-12 启动
  52. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  53. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  54. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects已终止NCT03591965研究中心II期2018-08 启动
  55. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  56. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  57. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  58. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  59. Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma已完成NCT02645981研究中心II/III期2016-03 启动
  60. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动
  61. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  62. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  63. Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma已完成NCT02229071研究中心I/II期2014-04 启动
  64. Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma已终止NCT02102022研究中心I/II期2014-11 启动
  65. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 168 篇,占 1.7%。

牵头论文
168
2021–2025 年
牵头试验
21
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 313120212022: 373720222023: 242420232024: 363620242025: 37372025

成都有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 15

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
    分期
    I/II期
    开始
    2024-12
    登记号
    NCT06742411

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  2. 即将招募
    Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
    分期
    II期
    开始
    2026-02
    登记号
    NCT07374250

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  3. 即将招募
    Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
    分期
    II期
    开始
    2026-07
    登记号
    NCT07655661

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:四川大学华西医院成都

  4. 邀请入组
    Non-surgical Management After NIT for dMMR/MSI-H GC
    分期
    未注明
    开始
    2026-07
    登记号
    NCT07646574

    年龄 18 岁 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

  5. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  6. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  7. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  8. 正在招募
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    分期
    II期
    开始
    2024-02
    登记号
    NCT06172478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州、成都

  9. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  10. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  11. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  12. 正在招募
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT07923214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、成都、福州

  13. 正在招募
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2023-04
    登记号
    NCT05918094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、广州、成都、武汉、郑州

  14. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    分期
    I期
    开始
    2022-02
    登记号
    NCT05262491

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南

  15. 即将招募
    Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07088744

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:海军军医大学第一附属医院(长海医院);另有 1 家列出的医院为研究中心上海、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术早期发现与内镜影像与人工智能
论文中的科室消化/肝病科普外/肝胆胰外科肿瘤内科病理/检验科
牵头的论文168
  1. The trajectories and predictors of cancer-related fatigue in gastric cancer patients during chemotherapy: A longitudinal study using growth mixture modeling.2026European journal of oncology nursing : the official journal of European Oncology Nursing Society
  2. The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: A meta-analysis.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages.2026International journal of surgery (London, England)
  4. HER2 regulates autophagy and promotes migration in gastric cancer cells through the cGAS-STING pathway.2025Anti-cancer drugs免费全文
  5. Prognostic value of nutritional risk assessment indices in patients with digestive system tumors.2025BMC cancer免费全文
  6. Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis.2025BMC gastroenterology免费全文
  7. Trends in incidence and mortality of early-onset gastrointestinal cancers: a comprehensive study.2025BMC gastroenterology免费全文
  8. Burden of gastrointestinal cancers in Asia, 1990-2019.2025BMC gastroenterology免费全文
  9. Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial.2025BMJ open免费全文
  10. Dihydroartemisinin suppresses metastatic potential and induces apoptosis in gastric adenocarcinoma: An integrative experimental and computational analysis revealing inhibition of MMP14 and promotion of oxidative stress.2025Bioorganic chemistry
  11. Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis.2025Cancer
  12. Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.2025Cancer medicine免费全文
  13. METTL3-driven m⁶A epigenetics in gastric cancer: unveiling oncogenic networks and clinical translation from tumorigenesis to therapy resistance.2025Cell biology and toxicology免费全文
  14. Proportion and Characteristics of Helicobacter Pylori -Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Systematic Review and Meta-Analysis.2025Clinical and translational gastroenterology免费全文
  15. 18 F-FDG PET/CT and 68 Ga-Pentixafor PET/CT Findings of Gastric Mucosa-associated Lymphoid Tissue Lymphoma Transformation to Diffuse Large B-cell Lymphoma.2025Clinical nuclear medicine
  16. Minimally invasive treatment strategies for submucosal tumors of the upper gastrointestinal tract: Advances in innovative endoscopy-based therapies.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial.2025Frontiers in immunology免费全文
  18. Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.2025Frontiers in immunology免费全文
  19. Hyperbaric oxygen therapy as an immunosensitizing strategy in advanced gastric hepatoid adenocarcinoma: a case report.2025Frontiers in immunology免费全文
  20. Integrated analysis of myeloperoxidase in gastric health and cancer: associations with pepsinogen levels, immune regulation, and prognosis in a large healthy population-based and TCGA cohorts.2025Frontiers in immunology免费全文
  21. Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.2025Frontiers in immunology免费全文
  22. Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis.2025International journal of biological macromolecules
  23. Lidocaine Enhanced Antitumor Efficacy and Relieved Chemotherapy-Induced Hyperalgesia in Mice with Metastatic Gastric Cancer.2025International journal of molecular sciences免费全文
  24. Targeted inhibition of gastric adenocarcinoma by nano-curcumin liposomes: Insights from combined machine learning and experimental analyses into the mechanisms of cuproptosis and metabolic reprogramming.2025International journal of pharmaceutics
  25. Impact of 68Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer.2025Journal of cancer research and clinical oncology免费全文
  26. GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.2025Journal of cellular and molecular medicine免费全文
  27. Effects of a Comprehensive Program on Reducing Cancer-Related Fatigue: A Randomized Controlled Trial.2025Journal of pain and symptom managementRCT
  28. EZH2 loss promotes gastric squamous cell carcinoma.2025Nature communications免费全文
  29. Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos/SREBF1 axis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  30. miRNA-204-5p acts as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and glycolysis via the RAB22A/PI3K/AKT axis.2025Scientific reports免费全文
  31. A novel prognostic model based on migrasome-related LncRNAs for gastric cancer.2025Scientific reports免费全文
  32. Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.2025Scientific reports免费全文
  33. Current status and influencing factors of cancer-related fatigue in gastric cancer patients undergoing chemotherapy: A cross-sectional study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  34. The impact of Helicobacter pylori infection on prognosis in patients with postgastrectomy gastric cancer: A systematic review and meta-analysis.2025Surgery
  35. Correlation of preoperative CT features with intra- and postoperative parameters of endoscopic resection in patients with gastric submucosal tumor (1~3 cm).2025Surgical endoscopy
  36. Intraperitoneal chemotherapy for gastric cancer.2025The Cochrane database of systematic reviews免费全文
  37. Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.2025The Journal of infectious diseases
  38. Efficacy and safety of S-1 plus oxaliplatin combined with apatinib and camrelizumab as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction adenocarcinoma: a protocol for a single-arm phase II trial.2025Updates in surgery
  39. Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study.2025World journal of surgical oncology免费全文
  40. A modified liver retraction method decreases liver dysfunction after laparoscopic gastrectomy.2025World journal of surgical oncology免费全文
  41. Enzyme-Responsive Branched Glycopolymer-Based Nanoassembly for Co-Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  42. Multicriteria optimization achieves superior normal tissue sparing in volumetric modulated arc therapy for gastric cancer.2024BMC cancer免费全文
  43. Endoscopic morphology of gastric MALT lymphoma correlate with API2/MALT1 fusion and predict treatment response after helicobacter pylori eradication.2024BMC gastroenterology免费全文
  44. Chemotherapy combined with immunotherapy in patients with gastric cancer: protocol for a systematic review.2024BMJ open免费全文
  45. Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.2024BMJ open免费全文
  46. Neoadjuvant and/or adjuvant chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: a systematic review and meta-analysis study protocol.2024BMJ open免费全文
  47. 68Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study.2024BMJ open免费全文
  48. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.2024Biochimica et biophysica acta. Molecular basis of disease
  49. Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer.2024Cancer letters
  50. Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.2024Cancer medicine免费全文
  51. CAF-secreted LOX promotes PD-L1 expression via histone Lactylation and regulates tumor EMT through TGFβ/IGF1 signaling in gastric Cancer.2024Cellular signalling
  52. Targeted plasma proteomic analysis uncovers a high-performance biomarker panel for early diagnosis of gastric cancer.2024Clinica chimica acta; international journal of clinical chemistry
  53. Maintaining H. pylori Negativity After Eradication Can Consolidate Its Benefit in Gastric Cancer Prevention: A Meta-Analysis.2024Clinical and translational gastroenterology免费全文
  54. Gastric Fundus Splenosis Mimicking Malignancy on FDG PET/CT.2024Clinical nuclear medicine
  55. Malignant gastric outlet obstruction: direct biopsy in the submucosal tunnel to obtain the diagnosis.2024Endoscopy免费全文
  56. Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.2024European journal of medicinal chemistry
  57. SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinica2024Frontiers in immunology免费全文
  58. Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study.2024Frontiers in immunology免费全文
  59. A novel suture technique for a large gastric defect after endoscopic full-thickness resection.2024Gastrointestinal endoscopy
  60. Comment on "Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study".2024International journal of cancer
  61. Combination of dexamethasone and dexmedetomidine as adjuvants of transversus abdominis plane block for postoperative analgesia in gastric cancer patients: A double-blinded randomized controlled trial.2024Journal of clinical anesthesiaRCT
  62. Gastrointestinal: Chronic anemia caused by diffuse lesions of the stomach.2024Journal of gastroenterology and hepatology
  63. Development and Validation of a Computed Tomography-Based Model for Noninvasive Prediction of the T Stage in Gastric Cancer: Multicenter Retrospective Study.2024Journal of medical Internet research免费全文
  64. Structural Optimization and Structure-Activity Relationship of 1H-Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity.2024Journal of medicinal chemistry
  65. Involvement of CXC chemokines (CXCL1-CXCL17) in gastric cancer: Prognosis and therapeutic molecules.2024Life sciences
  66. Symptom Cluster Assessment Tools for Gastric Cancer Care in China: A Comprehensive Review.2024Medical science monitor : international medical journal of experimental and clinical research免费全文
  67. The role of microRNAs in the gastric cancer tumor microenvironment.2024Molecular cancer免费全文
  68. Gastric SMARCA4-deficient undifferentiated tumor (SMARCA4-UT): a clinicopathological analysis of four rare cases.2024Orphanet journal of rare diseases免费全文
  69. Traditional Chinese medicine for gastric cancer: An evidence mapping.2024Phytotherapy research : PTR
  70. Optimal reconstruction methods after distal gastrectomy for gastric cancer: a protocol for a systematic review and network meta-analysis update.2024Systematic reviews免费全文
  71. Gastric Cancer Signaling Pathways and Therapeutic Applications.2024Technology in cancer research & treatment免费全文
  72. Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer.2024The Cochrane database of systematic reviews免费全文
  73. Managing crawling-type gastric adenocarcinoma with endoscopic techniques and postoperative monitoring.2024World journal of gastroenterology免费全文
  74. Early gastric composite tumor comprising signet-ring cell carcinoma and mucosa-associated lymphoid tissue lymphoma: A case report.2024World journal of gastroenterology免费全文
  75. Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future indication expansion.2024World journal of gastroenterology免费全文
  76. Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer.2024mSystems免费全文
  77. Effect of statin use on risk and mortality of gastric cancer: a meta-analysis.2023Anti-cancer drugs
  78. Trends in Incidence, Survival and Mortality of Gastric Cancer in the United States: A Population-Based Study, 2001-2015.2023Asian Pacific journal of cancer prevention : APJCP免费全文
  79. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.2023Cancer medicine免费全文
  80. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia.2023Cancer medicine免费全文
  81. Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.2023Cancer medicine免费全文
  82. Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial.2023Chinese medical journalRCT免费全文
  83. Hybrid Endoscopic Submucosal Dissection for Early Gastric Neoplasms: An Ideal Technique?2023Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  84. Calcified fibrous tumor in the stomach: a rare case of gastric submucosal tumor treated with endoscopic submucosal excavation.2023Endoscopy免费全文
  85. Gastritis cystica profunda mimicking submucosal tumor.2023Endoscopy免费全文
  86. Successful resection of a cavernous hemangioma involving the rectal muscularis propria layer by endoscopic full-thickness resection.2023Endoscopy免费全文
  87. The impact of the Hedgehog signal pathway on the tumor immune microenvironment of gastric adenocarcinoma by integrated analysis of scRNA-seq and RNA-seq datasets.2023Functional & integrative genomics
  88. Active Eradication of Helicobacter pylori Within Organized Massive Screening Might Improve Survival of Gastric Cancer Patients.2023Gastroenterology
  89. Krukenberg tumors metastasized from a T1a gastric carcinoma.2023Gastrointestinal endoscopy
  90. The potential role of artificial intelligence besides predicting gastric cancer invasion depth.2023Gastrointestinal endoscopy
  91. Discussion on the common controversies of Helicobacter pylori infection.2023Helicobacter
  92. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.2023International journal of molecular sciences免费全文
  93. The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.2023Journal of cancer research and clinical oncology免费全文
  94. Carrot and carotene and multiple health outcomes: an umbrella review of the evidence.2023Journal of the science of food and agriculture
  95. Association between nut consumption and cancer risk: a meta-analysis.2023Nutrition and cancer
  96. Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.2023Pathology oncology research : POR免费全文
  97. Whether preferences of gastric cancer patients after surgery for follow-up change over time? Analysis based on discrete choice experiment.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  98. A Gastrectomy for early-stage gastric cancer patients with or without preserving celiac branches of vagus nerves: A meta-analysis.2023Surgery
  99. Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.2023World journal of surgical oncology免费全文
  100. Clinical significance of tumor deposits in gastric cancer after radical gastrectomy: a propensity score matching study.2023World journal of surgical oncology免费全文
  101. Does endoscopic submucosal dissection have its place in the treatment of patients with gastric mucosa associated lymphoid tissue lymphoma localized disease after eradication?2022Acta gastro-enterologica Belgica
  102. Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.2022Anti-cancer drugs
  103. Clinicopathological characteristics and survival outcomes of patients with gallbladder neuroendocrine tumor.2022Asian journal of surgery
  104. Surgical replays-assisted diagnosis of duodenal stump fistula after laparoscopic radical distal gastrectomy (with video).2022Asian journal of surgery
  105. Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.2022BMC cancer免费全文
  106. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.2022Bioorganic chemistry
  107. Dissecting the genetic and microenvironmental factors of gastric tumorigenesis in mice.2022Cell reports
  108. Effects of EN combined with PN enriched with n-3 polyunsaturated fatty acids on immune related indicators and early rehabilitation of patients with gastric cancer: A randomized controlled trial.2022Clinical nutrition (Edinburgh, Scotland)RCT
  109. Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  110. Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery.2022Digestive diseases and sciences
  111. Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial.2022European journal of cancer (Oxford, England : 1990)
  112. Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer: 2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  113. What is the clinical value of prediction models in the management of gastric cancer?2022Gastrointestinal endoscopy
  114. Identifying Diagnostic and Prognostic Differentially Expressed Genes of Gastric Cancer Based on Bioinformatics Analyses of RNA-seq Data.2022Genetic testing and molecular biomarkers
  115. Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.2022Gynecologic oncology
  116. A commentary on "Safety and effectiveness of overlap esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: A systematic review and meta-analysis" (Int J Surg 2022; 102: 106684).2022International journal of surgery (London, England)
  117. A commentary on "Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review" (Int J Surg 2022;97:106184).2022International journal of surgery (London, England)
  118. Application of artificial intelligence in the endoscopic diagnosis of early gastric cancer, atrophic gastritis, and Helicobacter pylori infection.2022Journal of digestive diseases
  119. Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study.2022Journal of translational medicine免费全文
  120. Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.2022Langenbeck's archives of surgery
  121. Immunological Perspective: Helicobacter pylori Infection and Gastritis.2022Mediators of inflammation免费全文
  122. Multifactorial co-exposure within family of gastric cancer: increased risk of familial gastric cancer and tailored prevention.2022Medical oncology (Northwood, London, England)
  123. Deep learning-based AI model for signet-ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer.2022Medical physics
  124. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.2022Medicine免费全文
  125. Spicy Food and Chili Peppers and Multiple Health Outcomes: Umbrella Review.2022Molecular nutrition & food research免费全文
  126. Effects of Preoperative Oral Nutritional Supplements on Improving Postoperative Early Enteral Feeding Intolerance and Short-Term Prognosis for Gastric Cancer: A Prospective, Single-Center, Single-Blind, Randomized Controlled Trial.2022NutrientsRCT免费全文
  127. Efficacy of early enteral nutrition versus total parenteral nutrition for patients with gastric cancer complicated with diabetes mellitus: A systematic review and meta-analysis.2022Nutrition & dietetics : the journal of the Dietitians Association of Australia
  128. Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES).2022Nutrition and cancer
  129. The 'reversibility' of chronic atrophic gastritis after the eradication of Helicobacter pylori.2022Postgraduate medicine
  130. Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.2022Surgical endoscopy
  131. Artificial intelligence for diagnosing gastric lesions under white-light endoscopy.2022Surgical endoscopy
  132. Assessment of indocyanine green fluorescence lymphography on lymphadenectomy during minimally invasive gastric cancer surgery: a systematic review and meta-analysis.2022Surgical endoscopy
  133. Tibetan Ethnicity, Birthplace, Helicobacter pylori Infection, and Gastric Cancer Risk.2022The American journal of gastroenterology
  134. Correlation of Autoimmune Pancreatitis and Risk of Gastric Cancer in East Asian Population.2022The American journal of gastroenterology
  135. Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.2022The British journal of surgery免费全文
  136. Comment on: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.2022The British journal of surgery免费全文
  137. Effectiveness and safety of robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a meta-analysis of 12,401 gastric cancer patients.2022Updates in surgery
  138. Propensity score matching analysis for outcomes of laparoscopic versus open caudate lobectomy.2021ANZ journal of surgery
  139. Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study.2021Advances in therapy
  140. Development and validation of RNA binding protein-applied prediction model for gastric cancer.2021Aging免费全文
  141. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.2021Annals of palliative medicine
  142. The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.2021BMC cancer免费全文
  143. Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series.2021BMC gastroenterology免费全文
  144. Long-term endoscopic submucosal dissection with postoperative lung injury: a case report.2021BMC surgery免费全文
  145. Laparoscopic infrapyloric lymph nodes dissection through the right bursa omentalis approach for gastric cancer.2021BMC surgery免费全文
  146. Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis.2021BMJ open免费全文
  147. Impact of Surgical Margin Status on Survival in Gastric Cancer: A Systematic Review and Meta-Analysis.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  148. Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES).2021Cancer medicine免费全文
  149. Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  150. The Impact of Nerve Involvement on the Prognosis of Gastric Cancer Patients with Curative Gastrectomy: An International Multicenter Analysis.2021Disease markers免费全文
  151. Successful endoscopic submucosal dissection of a large juvenile polyp in the stomach of an infant.2021Endoscopy
  152. Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma.2021Expert review of anticancer therapy
  153. Tomato and lycopene and multiple health outcomes: Umbrella review.2021Food chemistry
  154. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.2021Future oncology (London, England)
  155. Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer.2021Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  156. Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathway.2021International journal of molecular medicine免费全文
  157. Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis.2021International journal of surgery (London, England)
  158. Monomorphic Epitheliotropic Intestinal T-cell Lymphoma of the Stomach: Two Case Reports and a Literature Review.2021International journal of surgical pathology
  159. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.2021JAMA network open免费全文
  160. The log odds of negative lymph nodes/T stage: a new prognostic and predictive tool for resected gastric cancer patients.2021Journal of cancer research and clinical oncology免费全文
  161. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies.2021Journal of cancer research and clinical oncology免费全文
  162. Comparisons of perioperative and survival outcomes of laparoscopic versus open gastrectomy for serosa-positive (pT4a) gastric cancer patients: a propensity score matched analysis.2021Langenbeck's archives of surgery
  163. Closure of Petersen's defect in gastrectomy for gastric cancer: an interrupted time series analysis from a high-volume institution in China.2021Langenbeck's archives of surgery免费全文
  164. The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.2021Surgery
  165. Application of clockwise modularized laparoscopic lymphadenectomy in the suprapancreatic area, a propensity score matching study and comparison with open gastrectomy.2021Surgical endoscopy免费全文
  166. Incidence of adhesive small bowel obstruction after gastrectomy for gastric cancer and its risk factors: a long-term retrospective cohort study from a high-volume institution in China.2021Updates in surgery
  167. Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.2021Virchows Archiv : an international journal of pathology
  168. The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis.2021Yonsei medical journal免费全文
中文论文(未计入)18
  1. [Current status and trends of perioperative immunotherapy for gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Exploration of the lymph node dissection range and strategies for adenocarcinoma of esophagogastric junction from the perspective of membrane anatomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Application and clinical significance of the "Four-Step Procedure" of laparoscopic exploration in the diagnosis of gastric cancer with peritoneal metastasis].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Prudent promotion of new surgical techniques for functional preservation of gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Network Pharmacology Study of Compound Ligustrazine in Gastric Cancer Therapy].2024Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  6. [Thinking about the extent and technique of lower mediastinal lymph nodes dissection for adenocarcinoma of esophagogastric junction].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Safety of patients undergoing radical resection combined with paclitaxel-based hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Interpretation of Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction(2024 edition)].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Analysis and Treatment Experience of 25 Cases of Primary Gastric Lymphoma with Acute Upper Gastrointestinal Bleeding as the Primary Manifestation].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  10. [Clinical Value of White Light Image, Endoscopic Ultrasonography and Magnifying Endoscopy with Narrow Band Imaging in Evaluation of Indications for Endoscopic Treatment of Early Gastric Cancer].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  11. [Comparison of postoperative mid-term and long-term quality of life between Billroth-I gastroduodenostomy and Billroth-II gastrojejunostomy after radical distal gastrectomy in patients with gastric cancer: a cohort study based on a case reg2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [How to master the clinical study on digestive tract reconstruction in gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Clinical significance of No.11p posterior lymph nodes dissection in gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. [Treatment of Siewert type II adenocarcinoma of the esophagogastric junction: the perspectives from thoracic surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  15. [MiR-4484 regulates the expression of integrin α 6 in gastric cancer tissues and its significance].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  16. [Utilizing Academic Clubs to Foster Practical Research Ability of Medical Students-Volunteer Team of Gastric Cancer Surgery of West China Hospital, Sichuan University].2021Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
  17. [Current status of diagnosis and treatment of gastric cancer peritoneal metastasis].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  18. [Risk factors of postoperative pulmonary infection of gastric cancer and perioperative intervention measures].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)51
  1. XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC正在招募NCT06742411牵头方I/II期2024-12 启动
  2. CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer进行中,不再招募NCT06667050牵头方II期2024-10 启动
  3. Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer状态不明NCT05640609牵头方I/II期2023-03 启动
  4. General Tissue Response Classification System After Chemotherapy状态不明NCT03791268牵头方2019-01 启动
  5. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712牵头方不分期2018-03 启动
  6. Systematic Review and Meta-analysis of Cereal or Grain Consumption and Gastric Cancer已完成NCT03419663牵头方2017-09 启动
  7. Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers已完成NCT05545293牵头方2017-09 启动
  8. CT Radiomics and Deep Learning-Based Non-Invasive Model for Tracing Primary Sites of Adenocarcinoma Liver Metastases: Automatic Differentiation of Multiple Primary Digestive Tumors已完成NCT07871019牵头方2015-01 启动
  9. Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors状态不明NCT02313688牵头方不分期2015-01 启动
  10. Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs状态不明NCT02436395牵头方不分期2015-05 启动
  11. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752牵头方不分期2014-10 启动
  12. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy状态不明NCT02110628牵头方III期2014-08 启动
  13. Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers状态不明NCT01911832牵头方III期2012-03 启动
  14. Non-surgical Management After NIT for dMMR/MSI-H GC邀请入组NCT07646574牵头方(推断)2026-07 启动
  15. Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma即将招募NCT07374250牵头方(推断)II期2026-02 启动
  16. Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.即将招募NCT07655661牵头方(推断)II期2026-07 启动
  17. Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction状态不明NCT04263870牵头方(推断)II期2020-03 启动
  18. Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)状态不明NCT03563326牵头方(推断)I期2018-08 启动
  19. EpCAM CAR-T for Treatment of Advanced Solid Tumors状态不明NCT02915445牵头方(推断)I期2016-07 启动
  20. Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer状态不明NCT02800005牵头方(推断)不分期2015-07 启动
  21. Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy已终止NCT02288728牵头方(推断)不分期2014-12 启动
  22. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  23. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  24. Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD即将招募NCT07088744研究中心2025-07 启动
  25. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822研究中心II期2025-12 启动
  26. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  27. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors正在招募NCT06172478研究中心II期2024-02 启动
  28. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  29. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  30. A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors正在招募NCT07923214研究中心I期2024-07 启动
  31. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT05918094研究中心III期2023-04 启动
  32. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor正在招募NCT05262491研究中心I期2022-02 启动
  33. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  34. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  35. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  36. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  37. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  38. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  39. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  40. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  41. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  42. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  43. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  44. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  45. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis状态不明NCT03023436研究中心III期2016-01 启动
  46. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  47. Study of Metatinib Tromethamine Tablet状态不明NCT02650375研究中心I期2015-10 启动
  48. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  49. Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma已终止NCT02102022研究中心I/II期2014-11 启动
  50. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  51. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.6%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 0020242025: 002025

成都有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

成都有 3 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科
牵头的论文1
  1. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.2023Biochimica et biophysica acta. Gene regulatory mechanisms
早期论文(2016–2020 年)2
  1. Effects of miR-26a on the expression of Beclin 1 in retinoblastoma cells.2016Genetics and molecular research : GMR
  2. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China.2016Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 2.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

成都有 4 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 36 篇,占 1.6%。

牵头论文
36
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 111120222023: 111120232024: 4420242025: 552025

成都有 13 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科耳鼻喉/头颈外科影像/核医学科肿瘤内科
牵头的论文36
  1. KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.2025Angiogenesis
  2. Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach.2025International journal of biological macromolecules
  3. Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration.2025Nature communications
  4. 3D-Printed Metacarpal Prosthesis in the Treatment of Primary Osteosarcoma of the First Metacarpal: A Novel Surgical Technique.2025Orthopaedic surgery
  5. 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.2025Orthopaedic surgery
  6. Tetrahedral Framework Nucleic Acid-Loaded Retinoic Acid Promotes Osteosarcoma Stem Cell Clearance.2024ACS applied materials & interfaces
  7. Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis.2024International journal of biological macromolecules
  8. Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors.2024International journal of molecular sciences
  9. Quality assessment of online osteosarcoma-related videos in Mainland China: A cross-sectional study.2024Journal of orthopaedic surgery (Hong Kong)
  10. Surgical Treatment of Osteosarcoma Induced Distant Pre-Metastatic Niche in Lung to Facilitate the Colonization of Circulating Tumor Cells.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  11. Primary hepatic carcinosarcoma with osteosarcoma components: A case report and literature review.2023Asian journal of surgery
  12. Bibliometric analysis of Ewing sarcoma from 1993 to 2022.2023BMC cancer
  13. Thiram, an inhibitor of 11ß-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt/β-catenin pathway.2023BMC pharmacology & toxicology
  14. Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine.2023Biomolecules
  15. The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.2023Cancer medicine
  16. Transformation of Cemento-Ossifying Fibroma into Osteosarcoma after Radiotherapy and Nine Endoscopic Surgeries.2023Ear, nose, & throat journal
  17. MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?2023International journal of medical sciences
  18. Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.2023Journal of radiology case reports
  19. Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.2023Pediatric blood & cancer
  20. Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry.2023Virchows Archiv : an international journal of pathology
  21. Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis.2022BMC musculoskeletal disorders
  22. Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?2022BMC surgery
  23. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.2022Cancer letters
  24. Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma.2022Frontiers in immunology
  25. Characteristics and prognosis of primary pulmonary osteosarcoma: a pooled analysis.2022Journal of cardiothoracic surgery
  26. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.2022Journal of experimental & clinical cancer research : CR
  27. Use of Nomogram on Nutritional Assessment Indicators to Predict Clinical Outcomes in Patients Undergoing Surgical Resection for High-Grade Osteosarcoma.2022Nutrition and cancer
  28. 3D Customized Biological Tibial Intramedullary Nail Fixation for the Treatment of Fracture after Massive Allograft Bone Transplantation of Tibial Osteosarcoma: A Case Report.2022Orthopaedic surgery
  29. The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: A systematic review of in vitro experiment and animal model reports.2022Photodiagnosis and photodynamic therapy
  30. Primary Osteosarcoma of Left Atrial Appendage in a Patient with Rheumatic Heart Disease.2022The heart surgery forum
  31. A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.2022Thoracic cancer
  32. 3D-Printed Multifunctional Polyetheretherketone Bone Scaffold for Multimodal Treatment of Osteosarcoma and Osteomyelitis.2021ACS applied materials & interfaces
  33. 3D Printed Multifunctional Ti6Al4V-Based Hybrid Scaffold for the Management of Osteosarcoma.2021Bioconjugate chemistry
  34. Progress of Phototherapy Applications in the Treatment of Bone Cancer.2021International journal of molecular sciences
  35. Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.2021Journal of nanobiotechnology
  36. Askin tumor in the chest wall.2021Thoracic cancer
中文论文(未计入)2
  1. [A case of secretory otitis media caused by extraskeletal Ewing's sarcoma of parapharyngeal skull base and literature review].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
  2. [Long-term effectiveness of uncemented allograft-prosthesis composite for reconstruction of bone defects after proximal femur tumor resection].2023Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
早期论文(2016–2020 年)22
  1. PTEN in osteosarcoma: Recent advances and the therapeutic potential.2020Biochimica et biophysica acta. Reviews on cancer
  2. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.2020IUBMB life
  3. Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.2020International journal of oncology
  4. A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.2020Scientific reports
  5. RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.2019Anti-cancer drugs
  6. Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.2019Cell cycle (Georgetown, Tex.)
  7. Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma.2019Investigational new drugs
  8. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  9. SP1-induced upregulation of long non-coding RNA HCP5 promotes the development of osteosarcoma.2019Pathology, research and practice
  10. Total ulna replacement with a 3D-printed custom-made prosthesis after en bloc tumor resection: A case report.2019Pediatric blood & cancer
  11. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.2018Histopathology
  12. [Therapeutic Effect of Uncemented Allograft-prosthetic Composite for the Reconstruction of Tumorous Bone Defect].2018Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  13. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.2018The American journal of surgical pathology
  14. Uncemented three-dimensional-printed prosthetic reconstruction for massive bone defects of the proximal tibia.2018World journal of surgical oncology
  15. Integrated bioinformatics analysis of miRNA expression in osteosarcoma.2017Artificial cells, nanomedicine, and biotechnology
  16. Successful removal of giant primary osteosarcoma in the anterior mediastinum invading the superior vena cava and right lung with artificial blood vessel reconstruction.2017European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  17. Primary Left Atrial Osteosarcoma.2017International heart journal
  18. A multi-level comparative analysis of human femoral cortical bone quality in healthy cadavers and surgical safe margin of osteosarcoma patients.2017Journal of the mechanical behavior of biomedical materials
  19. A case report of apatinib in treating osteosarcoma with pulmonary metastases.2017Medicine
  20. Antidifferentiation Noncoding RNA Regulates the Proliferation of Osteosarcoma Cells.2016Cancer biotherapy & radiopharmaceuticals
  21. A rare case of extensive primary meningeal osteosarcoma in childhood.2016Neurology
  22. Congenital Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature.2016Pediatrics and neonatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma状态不明NCT05194605牵头方2021-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 33 篇,占 6.3%。

牵头论文
33
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 111120222023: 6620232024: 3320242025: 442025

成都有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科病理/检验科影像/核医学科普外/肝胆胰外科
牵头的论文33
  1. Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.2026Abdominal radiology (New York)
  2. NF1 Mutated Gastrointestinal Stromal Tumors With Coamplification of MDM2 and MYC.2025Genes, chromosomes & cancer
  3. Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.2025Pathology, research and practice
  4. Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study.2025Scandinavian journal of gastroenterology
  5. The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: a propensity score-matched analysis.2025Surgical endoscopy
  6. FDG PET/CT Image of Extragastrointestinal Stromal Tumor in the Posterior Mediastinum.2024Clinical nuclear medicine
  7. Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape.2024Frontiers in immunology
  8. Analysis of the diagnostic value of CT radiomics models in differentiating GIST and other mesenchymal tumors.2024Hellenic journal of nuclear medicine
  9. Wild-type gastrointestinal stromal tumors with NTRK gene fusions: A clinicopathological study.2023Asian journal of surgery
  10. Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report.2023Asian journal of surgery
  11. Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature.2023BMC cancer
  12. Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.2023Cancer medicine
  13. Impact of surgical resection for gastrointestinal stromal tumor (GIST) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  14. DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis.2023Frontiers in immunology
  15. Two-staged hepatectomy for bilobar metastases of the gastrointestinal stromal tumor (GIST).2022Asian journal of surgery
  16. Primary hepatic gastrointestinal stromal tumor: A case series.2022Asian journal of surgery
  17. Open and minimally invasive surgery for gastrointestinal stromal tumours: a systematic review and network meta-analysis protocol.2022BMJ open
  18. The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.2022British journal of cancer
  19. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.2022Cancer medicine
  20. Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  21. Cap-assisted endoscopic full-thickness resection for small gastrointestinal stromal tumors.2022Gastrointestinal endoscopy
  22. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.2022Journal of cancer research and clinical oncology
  23. Surgical strategies for duodenal gastrointestinal stromal tumors.2022Langenbeck's archives of surgery
  24. Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.2022Surgical endoscopy
  25. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study.2022World journal of gastroenterology
  26. Use of computed tomography for distinguishing heterotopic pancreas from gastrointestinal stromal tumor and leiomyoma.2021Abdominal radiology (New York)
  27. Primary retroperitoneal gastrointestinal stromal tumor mimicking adrenal mass: A case report.2021Asian journal of surgery
  28. Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy.2021BMC surgery
  29. Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors.2021Cell death & disease
  30. Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  31. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review.2021Frontiers in public health
  32. Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update.2021Systematic reviews
  33. Transperineal core-needle biopsy of a rectal subepithelial lesion guided by endorectal ultrasound after contrast-enhanced ultrasound: A case report.2021World journal of gastroenterology
中文论文(未计入)2
  1. [Clinicopathological characteristics and prognosis of patients with small bowel tumors: A single center analysis of 220 cases].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Study of neurotrophic factor receptor tyrosine kinase gene fusion in the precise treatment of wild-type gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)28
  1. Current and Potential Applications of Artificial Intelligence in Gastrointestinal Stromal Tumor Imaging.2020Contrast media & molecular imaging
  2. Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction: A single-center review of 136 cases.2020Medicine
  3. Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.2020Medicine
  4. [Efficacy of Transcatheter Embolization for Gastrointestinal Stromal Tumor with Gastrointestinal Hemorrhage in 17 Cases].2020Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  5. Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study.2020World journal of surgical oncology
  6. [Clinical diagnosis and treatment of gastrointestinal stromal tumor: matching technological breakthrough with patient care].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. Endoscopic full-thickness resection for a duodenal gastrointestinal stromal tumour.2019Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  8. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.2019Cell proliferation
  9. Primary Gastrointestinal Stromal Tumor of the Liver.2019Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  10. Diffuse ileal ganglioneuromatosis mimicking a gastrointestinal stromal tumor: A case report.2019Medicine
  11. Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review.2019Medicine
  12. Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs.2019Medicine
  13. Proteomic Maps of Human Gastrointestinal Stromal Tumor Subgroups.2019Molecular & cellular proteomics : MCP
  14. Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors.2019Scientific reports
  15. [Real world study and its application in gastrointestinal stromal tumor].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.2018BMC gastroenterology
  17. Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: A systematic review and meta-analysis.2018International journal of surgery (London, England)
  18. Comparison Analysis of Three Different Types of Minimally Invasive Procedures for Gastrointestinal Stromal Tumors ≤5 cm.2018Journal of laparoendoscopic & advanced surgical techniques. Part A
  19. Effect of Gastrointestinal Bleeding on Gastrointestinal Stromal Tumor Patients: A Retrospective Cohort Study.2018Medical science monitor : international medical journal of experimental and clinical research
  20. Giant gastric stromal tumor mimicking as a posterior mediastinal mass: A case report and literature review.2018Medicine
  21. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.2018Medicine
  22. Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.2017Scientific reports
  23. [Associations of Preoperative Platelet-to-lymphocyte Ratio and Derived Neutrophil-to-lymphocyte Ratio with thePrognosis of Gastrointestinal Stromal Tumor].2017Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  24. [FAP Expression and Its Association with the Prognosis of Gastric Stromal Tumors].2017Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  25. Laparoscopic Versus Open Resection for Gastric Gastrointestinal Stromal Tumors (GISTs): A Size-Location-Matched Case-Control Study.2017World journal of surgery
  26. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).2017World journal of surgical oncology
  27. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.2016Medicine
  28. [Preliminary understanding of gastrointestinal stromal tumor with the highest risk].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)正在招募NCT04924075研究中心II期2021-08 启动
  3. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)已完成NCT04282980研究中心II期2020-04 启动
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动
  6. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST状态不明NCT02776878研究中心不分期2016-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

成都有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
    分期
    早期I期
    开始
    2026-07
    登记号
    NCT07767630

    年龄 1 岁 至 100 岁(登记的条件)

    牵头:四川大学华西医院成都

  2. 正在招募
    Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
    分期
    早期I期
    开始
    2025-07
    登记号
    NCT07067346

    年龄 12 个月 至 未注明(登记的条件)

    牵头:四川大学华西医院成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科影像/核医学科
牵头的论文5
  1. TSPYL5-driven G3BP1 nuclear membrane translocation facilitates p53 cytoplasm sequestration via accelerating RanBP2-mediated p53 sumoylation and nuclear export in neuroblastoma.2025Cell death & disease
  2. The Complementary Role of 68 Ga-FAPI-04 PET/CT in a Case of Neuroblastoma.2024Clinical nuclear medicine
  3. Contrast computed tomography-based radiomics is correlation with COG risk stratification of neuroblastoma.2023Abdominal radiology (New York)
  4. Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis.2022Angiogenesis
  5. Hyperthermia in a pediatric patient with neuroblastoma during anesthesia: a case report.2021BMC surgery
早期论文(2016–2020 年)5
  1. The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH.2020Cell transplantation
  2. Primary orbital ganglioneuroblastoma in a child: A case report.2020Medicine
  3. The effect of age distribution on the prognosis of retroperitoneal neuroblastoma.2020Medicine
  4. Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis.2019Journal of pediatric surgery
  5. Primary cervical ganglioneuroblastoma: A case report.2018Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children状态不明NCT05179850牵头方2021-01 启动
  2. Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma正在招募NCT07767630牵头方(推断)早期I期2026-07 启动
  3. Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma正在招募NCT07067346牵头方(推断)早期I期2025-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 5.5%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 0020242025: 222025

成都有 2 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科影像/核医学科
牵头的论文9
  1. KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.2025Angiogenesis
  2. 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.2025Orthopaedic surgery
  3. Bibliometric analysis of Ewing sarcoma from 1993 to 2022.2023BMC cancer
  4. The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.2023Cancer medicine
  5. Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.2023Journal of radiology case reports
  6. Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.2023Pediatric blood & cancer
  7. Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?2022BMC surgery
  8. A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.2022Thoracic cancer
  9. Askin tumor in the chest wall.2021Thoracic cancer
中文论文(未计入)1
  1. [A case of secretory otitis media caused by extraskeletal Ewing's sarcoma of parapharyngeal skull base and literature review].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
早期论文(2016–2020 年)2
  1. [Therapeutic Effect of Uncemented Allograft-prosthetic Composite for the Reconstruction of Tumorous Bone Defect].2018Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  2. Congenital Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature.2016Pediatrics and neonatology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 59 篇,占 3.5%。

牵头论文
59
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 8820222023: 141420232024: 161620242025: 11112025

成都有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    分期
    I期
    开始
    2026-03
    登记号
    NCT07255898

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都

  2. 正在招募
    A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
    分期
    I期
    开始
    2024-08
    登记号
    NCT06484777

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都

  3. 正在招募
    Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-03
    登记号
    NCT06484829

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心成都

  4. 正在招募
    A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
    分期
    I期
    开始
    2024-11
    登记号
    NCT06700395

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、成都

  5. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层复发与耐药
论文中的科室病理/检验科神经内科影像/核医学科临床试验/研究机构
牵头的论文59
  1. Single-cell RNA sequencing reveals immune regulatory mechanisms and molecular therapeutic strategies in the microenvironment of multiple myeloma.2026International journal of surgery (London, England)免费全文
  2. Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation.2025BMJ open免费全文
  3. LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma.2025Biochemical pharmacology
  4. The mitochondrial protease ClpP is a promising target for multiple myeloma treatment.2025Biochemical pharmacology
  5. A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma.2025British journal of haematology免费全文
  6. Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma.2025Cancer medicine免费全文
  7. Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.2025Cancer medicine免费全文
  8. Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells.2025International immunopharmacology
  9. Beneficial effects of aerobic exercises on multiple myeloma: Mechanisms and clinical observations.2025International journal of cancer
  10. A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease.2025Journal of cancer research and clinical oncology免费全文
  11. Impact of integrated nursing care on rehabilitation process of inpatients with multiple myeloma in an academic hematology department.2025MedicineRCT免费全文
  12. Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.2025Signal transduction and targeted therapy免费全文
  13. Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.2024British journal of haematology
  14. Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.2024Cancer letters
  15. RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.2024Cancer letters
  16. A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.2024Cancer medicine免费全文
  17. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.2024Cancer medicine免费全文
  18. Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib.2024Cell death & disease免费全文
  19. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.2024Clinical and experimental medicine免费全文
  20. Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.2024Clinical and experimental medicine免费全文
  21. CAR-T Therapy in Relapsed Refractory Multiple Myeloma.2024Current medicinal chemistry免费全文
  22. Clinical significance of T helper cell subsets in the peripheral blood and bone marrow of patients with multiple myeloma.2024Frontiers in immunology免费全文
  23. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.2024Frontiers in immunology免费全文
  24. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.2024Journal of nanobiotechnology免费全文
  25. Multiple myeloma: signaling pathways and targeted therapy.2024Molecular biomedicine免费全文
  26. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.2024Oncology research免费全文
  27. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.2024Signal transduction and targeted therapy免费全文
  28. Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.2024The journal of gene medicine
  29. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.2023Cancer letters
  30. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.2023Cancer letters
  31. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.2023Cancer letters
  32. Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: A UK biobank cohort study.2023Cancer medicine免费全文
  33. Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.2023Cancer medicineRCT免费全文
  34. A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.2023Cancer medicine免费全文
  35. Hypermetabolic Subserosal Uterine Leiomyoma With Synchronous Atypical Multiple Myeloma Mimicking Ovarian Malignancy With Multiple Bone Metastases on 18F-FDG PET/CT.2023Clinical nuclear medicine
  36. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.2023European journal of medicinal chemistry
  37. Case report: Vesiculobullous eruption with an atypical IgA deposition pattern in a patient with multiple myeloma-A case report and literature review.2023Frontiers in immunology免费全文
  38. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.2023Hematology (Amsterdam, Netherlands)
  39. A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy.2023International immunopharmacology
  40. Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.2023Life sciences
  41. Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey.2023Nutrients免费全文
  42. Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies.2023Nutrition and cancer
  43. Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.2022Advanced materials (Deerfield Beach, Fla.)
  44. ALCAM regulates multiple myeloma chemoresistant side population.2022Cell death & disease免费全文
  45. Site-specific N-glycosylation characterization of micro monoclonal immunoglobulins based on EThcD-sceHCD-MS/MS.2022Frontiers in immunology免费全文
  46. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.2022Hematology (Amsterdam, Netherlands)
  47. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.2022JCI insight免费全文
  48. Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease.2022Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  49. FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.2022Journal of hematology & oncology免费全文
  50. Symptom clusters and quality of life in ambulatory patients with multiple myeloma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  51. Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.2021Annals of hematology
  52. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomise2021BMC cancer免费全文
  53. Extramedullary intracardiac multiple myeloma misdiagnosed as a thrombus: a case report.2021BMC surgery免费全文
  54. BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.2021Cell death & disease免费全文
  55. Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.2021Chinese medical journal免费全文
  56. Multiple Myeloma Presenting as Disseminated Osteoblastic Lesions With Intense 18F-FDG Uptake on PET/CT.2021Clinical nuclear medicine
  57. Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma.2021Frontiers in immunology免费全文
  58. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.2021Journal of medicinal chemistry
  59. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.2021Medicine免费全文
中文论文(未计入)5
  1. [Advances in Modeling of Multiple Myeloma in Mice].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  2. [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  4. [Full-cycle Health Management of Multiple Myeloma].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  5. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)21
  1. CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma状态不明NCT04727008牵头方(推断)I期2022-09 启动
  2. Selinexor in Combination With Thalidomide and Dexamethasone in RRMM状态不明NCT04891744牵头方(推断)I/II期2021-07 启动
  3. A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies正在招募NCT07255898研究中心I期2026-03 启动
  4. A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma正在招募NCT06700395研究中心I期2024-11 启动
  5. A Clinical Study of SHR-9539 in Patients With Multiple Myeloma正在招募NCT06484777研究中心I期2024-08 启动
  6. Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT06484829研究中心I/II期2024-03 启动
  7. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  9. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  10. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  11. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  12. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  13. A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule状态不明NCT04275583研究中心I期2020-05 启动
  14. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  15. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  16. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  17. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  18. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  19. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  20. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动
  21. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma已完成NCT00689936研究中心III期2008-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

成都有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  2. 正在招募
    Phase Ib Clinical Study of Keynatinib
    分期
    I期
    开始
    2020-09
    登记号
    NCT04807881

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与靶向药物费城染色体与遗传学微小残留病与复发

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 222025

成都有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题干细胞移植克隆演变与 PNH免疫抑制治疗

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 12 篇,占 3.0%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 5520222023: 2220232024: 3320242025: 222025

成都有 3 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题淋巴瘤及肿瘤相关噬血EB病毒与感染诱因诊断与预后
论文中的科室肾内科肿瘤内科影像/核医学科
牵头的论文12
  1. Flow cytometric analysis of the immune cell subsets in adult hemophagocytic lymphohistiocytosis.2025Frontiers in immunology免费全文
  2. Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.2025Future oncology (London, England)免费全文
  3. Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review.2024Frontiers in immunology免费全文
  4. Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) coinfected with COVID-19 complicated by hemophagocytic lymphohistiocytosis: a case report.2024Frontiers in immunology免费全文
  5. Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.2024Journal of hematology & oncology免费全文
  6. Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis.2023Annals of hematology
  7. The predictive value of hematological inflammatory markers for acute kidney injury and mortality in adults with hemophagocytic Lymphohistiocytosis: A retrospective analysis of 585 patients.2023International immunopharmacology
  8. A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.2022Frontiers in immunology免费全文
  9. Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.2022Frontiers in immunology免费全文
  10. Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.2022Hematology (Amsterdam, Netherlands)
  11. Clinical features and prognostic factors of acute kidney injury caused by adult secondary hemophagocytic lymphohistiocytosis.2022Journal of nephrology
  12. Case Report: Visceral Leishmaniasis-associated Hemophagocytic Lymphohistiocytosis in Adults: A Case Series and Literature Review.2022The American journal of tropical medicine and hygiene免费全文
中文论文(未计入)1
  1. [Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome].2022Zhonghua yi xue za zhi
PubMed 以外找到的论文(未计入)18
  1. Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025Blood会议摘要
  2. Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis2025Blood会议摘要
  3. Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis2025Blood会议摘要
  4. Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital2025Blood会议摘要
  5. Chronic active EBV infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia2024未列出期刊预印本
  6. Clinical Characteristics and Prognosis of Subcutaneous Panniculitis-like T-Cell Lymphoma Based on the SEER Database2024Blood会议摘要
  7. Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis2024Blood会议摘要
  8. Herombopag, a Second Generation Thrombopoietin-Receptor Agonist, Stimulates Platelet Engraftment after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation2023Blood会议摘要
  9. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)论文
  10. Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement2022Blood会议摘要
  11. Familial hemophagocytic lymphohistiocytosis with Epstein–Barr virus infection and progression to aggressive NK-cell leukemia: a case report and review of the literature2022Journal of Hematopathology论文
  12. Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone2022Blood论文
  13. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Blood论文
  14. Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study2022Research Square预印本
  15. Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study2022Research Square预印本
  16. Chronic active EB virus infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia: a case report and review of the literature2021Research Square预印本
  17. Development and Initial Validation of a Novel Prognostic Model in Adult Secondary Hemophagocytic Lymphohistiocytosis Patients: Experience From a Single-center Retrospective Study2021Research Square预印本
  18. MO412THE RISK FACTORS OF ACUTE KIDNEY INJURY CAUSED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS2021Nephrology Dialysis Transplantation论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

成都有 6 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    分期
    II期
    开始
    2019-11
    登记号
    NCT04143724

    年龄 6 岁 至 17 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

成都有 6 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

成都有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文2
  1. Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy for essential thrombocythemia: a case report.2023BMC nephrology
  2. Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review.2023Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

成都有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
牵头的论文1
  1. Diagnosis and Management of Fanconi Anemia.2025Journal of evidence-based medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 36 篇,占 7.4%。

牵头论文
36
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 7720222023: 9920232024: 6620242025: 662025

成都有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断影像视神经与视力
论文中的科室神经内科病理/检验科神经外科
牵头的论文36
  1. Glymphatic dysfunction in neuromyelitis optica spectrum disorder.2025Frontiers in immunology免费全文
  2. Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.2025Journal of neurology
  3. Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.2025Journal of neurology
  4. Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.2025Journal of neurology
  5. Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.2025Journal of neurology
  6. A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.2025Journal of neurology
  7. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.2024European journal of neurology免费全文
  8. Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab.2024Frontiers in immunology免费全文
  9. Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection.2024JAMA neurology
  10. Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.2024Journal of neuroimmunology
  11. Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.2024Journal of neurology
  12. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.2024Journal of neurology
  13. Initial BMI effects on clinical presentation and prognosis in neuromyelitis optica spectrum disorder.2023Annals of clinical and translational neurology免费全文
  14. COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.2023Frontiers in immunology免费全文
  15. Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models.2023Frontiers in immunology免费全文
  16. Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study.2023Frontiers in immunology免费全文
  17. Non-immune system comorbidity in neuromyelitis optica spectrum disorders.2023Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
  19. Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.2023Journal of neurology
  20. Investigation on marital status of patients with neuromyelitis optica spectrum disorders in China.2023Multiple sclerosis and related disorders
  21. Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders.2023Neurology(R) neuroimmunology & neuroinflammation免费全文
  22. Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.2022Annals of clinical and translational neurology免费全文
  23. Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder.2022BMC neurology免费全文
  24. Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders.2022Frontiers in immunology免费全文
  25. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.2022Frontiers in immunology免费全文
  26. Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.2022Frontiers in immunology免费全文
  27. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.2022Multiple sclerosis and related disorders免费全文
  28. Sparser macula microvasculature in neuromyelitis optica spectrum disorder occurs independently of optic neuritis.2022Multiple sclerosis and related disorders
  29. Mortality of neuromyelitis optica spectrum disorders in a Chinese population.2021Annals of clinical and translational neurology免费全文
  30. CD8+ T cell subpopulations and pro-inflammatory cytokines in neuromyelitis optica spectrum disorder.2021Annals of clinical and translational neurology免费全文
  31. The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway.2021Cell proliferation免费全文
  32. Neuromyelitis Optica Spectrum Disorder With Hyponatremia as an Initial Presentation: A Case Report.2021Clinical therapeutics
  33. Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.2021Journal of neuroimmunology
  34. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.2021Journal of neuroimmunology
  35. Brain changes correlate with neuropathic pain in patients with neuromyelitis optica spectrum disorders.2021Multiple sclerosis and related disorders
  36. Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report.2021The journal of spinal cord medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. An Open Label Study of the Effects of SHR1459 in NMOSDs Patients已完成NCT04670770研究中心II期2021-01 启动
PubMed 以外找到的论文(未计入)1
  1. Prognosis of Neuromyelitis Optica Spectrum Disorders: Differences Between Han Chinese and Tibetans, a retrospective cohort study2022Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.5%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 1120242025: 662025

成都有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    分期
    I/II期
    开始
    2026-01
    登记号
    NCT07061938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题头颈、眼眶与唾液腺治疗与复发诊断与鉴别
论文中的科室眼科/神经眼科肾内科病理/检验科风湿免疫科
牵头的论文11
  1. Immunoglobulin G4-related disease with pleural involvement in an 80-year-old female patient: A case report and literature review.2025Experimental gerontology
  2. IgG4-related disease presenting with hypercalcemia: case report and mechanistic insights.2025Frontiers in immunology免费全文
  3. Case Report: IgG4-RD-related ophthalmopathy combined with monoclonal gammopathy of undetermined significance.2025Frontiers in immunology免费全文
  4. Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease.2025Frontiers in immunology免费全文
  5. Similarities and differences of a proliferation-inducing ligand expression in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases and mucosa-associated lymphoid tissue lymphoma.2025Frontiers in immunology免费全文
  6. Immunoglobulin G4-related ophthalmic disease with orbital deep hemangioma: A case report.2025The Journal of international medical research免费全文
  7. Clinicopathologic features and outcomes of bilateral lacrimal gland lesions.2024PloS one免费全文
  8. Clinical Significance of Serum IgG4 in the Diagnosis and Treatment Response of IgG4-Related Disease in Adults of Southwest China: A Retrospective Study.2023Annals of laboratory medicine免费全文
  9. Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease.2023JCI insight免费全文
  10. Malignancies in Chinese patients with immunoglobulin G4-related disease.2021Clinical and experimental rheumatology
  11. IgG4-Related Disease With Tuberculosis: A Case Report and Retrospective Review of Patients in a Single Center.2021Frontiers in immunology免费全文
中文论文(未计入)1
  1. [Research progress in IgG4-related pharyngolaryngeal disease].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease正在招募NCT07061938研究中心I/II期2026-01 启动
  2. A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease进行中,不再招募NCT05662241研究中心III期2023-01 启动
PubMed 以外找到的论文(未计入)1
  1. PB1953: TWELVE CASES OF MULTICENTRIC CASTLEMAN DISEASE WITH ELEVATED SERUM IGG4 LEVELS AND INFILTRATING IGG4 POSITIVE PLASMA CELLS PATHOLOGICALLY FROM A SINGLE CENTER.2023HemaSphere会议摘要

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 16 篇,占 3.2%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 4420232024: 2220242025: 882025

成都有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

  2. 正在招募
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    分期
    III期
    开始
    2024-06
    登记号
    NCT06463587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙

  3. 正在招募
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    分期
    II期
    开始
    2022-07
    登记号
    NCT05067348

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙

  4. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题胸腺与胸腺切除生物制剂与补体抑制剂常规免疫治疗
论文中的科室神经内科眼科/神经眼科
牵头的论文16
  1. The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.2025European journal of medical research免费全文
  2. The Role of Exosomes in Central Immune Tolerance and Myasthenia Gravis.2025Immunological investigations
  3. Clinical study of thyroid eye disease combined with myasthenia gravis.2025Japanese journal of ophthalmology
  4. Identification of Novel Protein Biomarkers for Myasthenia Gravis by Integrating Human Proteomics with Genetic Instruments.2025Journal of proteome research
  5. The mortality of myasthenia gravis with myocarditis: A single-center retrospective study.2025Journal of the neurological sciences
  6. The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.2025Neurocritical care
  7. Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.2025Orphanet journal of rare diseases免费全文
  8. Efficacy and Safety of Tacrolimus Therapy in Patients With Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis.2025Pediatric neurology
  9. The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.2024Brain and behavior免费全文
  10. Mendelian randomization study revealed a gut microbiota-neuromuscular junction axis in myasthenia gravis.2024Scientific reports免费全文
  11. Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?2023Autoimmunity reviews
  12. Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.2023Brain and behavior免费全文
  13. Unexpected fibrous mediastinitis in a patient with myasthenia gravis - a case report.2023Journal of cardiothoracic surgery免费全文
  14. Safety and feasibility of a modularized procedure for trans-subxiphoid robotic extended thymectomy.2023Surgical endoscopy
  15. More ectopic thymic tissues resection results in a better outcome for patients with myasthenia gravis†.2021European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  16. Sexual dysfunction in patients with myasthenia gravis.2021Journal of neuroimmunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动
  2. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)正在招募NCT06463587研究中心III期2024-06 启动
  3. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis正在招募NCT05067348研究中心II期2022-07 启动
  4. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  5. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis状态不明NCT05716035研究中心II/III期2023-04 启动
  6. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  7. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis已终止NCT04963270研究中心III期2021-10 启动
  8. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis已完成NCT04302103研究中心II期2020-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.1%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 2220242025: 332025

成都有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流血管重建手术中风与出血
论文中的科室神经外科影像/核医学科
牵头的论文11
  1. Drug-Coated Balloon Treatment for LAD CTO in a Young Woman With Moyamoya Disease Guided by Intravascular Imaging.2025Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  2. Association between angiographic and clinical outcomes after STA-MCA bypass in adult moyamoya disease.2025European stroke journal免费全文
  3. Long-term outcomes after revascularization surgery for adult moyamoya disease: Protocol for systematic review and meta-analysis.2025PloS one免费全文
  4. Successful perioperative management of a patient undergoing laparoscopic colon surgery with high-risk of cerebral ischemia due to moyamoya disease.2024Asian journal of surgery
  5. Ivy Sign: Usefulness in Diagnosis and Prognosis Prediction of Moyamoya Disease.2024World neurosurgery
  6. Nomogram to Predict Good Collateral Formation After the STA-MCA Bypass Surgery in Adult Patients With Moyamoya Disease.2023Stroke
  7. Imaging methods for surgical revascularization in patients with moyamoya disease: an updated review.2022Neurosurgical review免费全文
  8. Angiographic and Hemodynamic Features in Asymptomatic Hemispheres of Patients With Moyamoya Disease.2022Stroke
  9. Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease in Adults with Moyamoya Disease.2022Translational stroke research
  10. Hemorrhagic stroke caused by moyamoya disease in a patient with obstructive hypertrophic cardiomyopathy.2021Chinese medical journal免费全文
  11. Clinical and Hemodynamic Features in Moyamoya Disease with Intracranial Aneurysms.2021World neurosurgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107研究中心2026-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.3%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 0020222023: 0020232024: 0020242025: 112025

成都有 2 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题Kasai手术长期结局肝移植
论文中的科室儿科病理/检验科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 22 篇,占 8.3%。

牵头论文
22
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 6620222023: 1120232024: 8820242025: 332025

成都有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科
牵头的论文22
  1. Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.2025Annals of neurology
  2. Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoring.2025Clinical immunology (Orlando, Fla.)
  3. Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial.2025Journal of neurology, neurosurgery, and psychiatryRCT
  4. The potential role of tACS in improving cognitive dysfunction associated with anti-NMDAR encephalitis.2024Asian journal of psychiatry
  5. Antibody-secreting cells as a source of NR1-IgGs in N-methyl-D-aspartate receptor-antibody encephalitis.2024Brain, behavior, and immunity
  6. Intestinal dysbiosis exacerbates susceptibility to the anti-NMDA receptor encephalitis-like phenotype by changing blood brain barrier permeability and immune homeostasis.2024Brain, behavior, and immunity
  7. Cortical atrophy in early-stage patients with anti-NMDA receptor encephalitis: a machine-learning MRI study with various feature extraction.2024Cerebral cortex (New York, N.Y. : 1991)
  8. Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: A multicenter prospective cohort study.2024Epilepsia
  9. Blood and CSF findings of cellular immunity in anti-NMDAR encephalitis.2024International immunopharmacology
  10. Genome-Wide Association Study Identifies IFIH1 and HLA-DQB1*05:02 Loci Associated With Anti-NMDAR Encephalitis.2024Neurology(R) neuroimmunology & neuroinflammation
  11. Single-cell RNA sequencing reveals diverse B cell phenotypes in patients with anti-NMDAR encephalitis.2024Psychiatry and clinical neurosciences
  12. Patient characteristics and outcome in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  13. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.2022Epilepsia
  14. Efficacy and tolerability of intravenous immunoglobulin versus intravenous methylprednisolone treatment in anti-N-methyl-d-aspartate receptor encephalitis.2022European journal of neurology
  15. Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis.2022Frontiers in immunology
  16. Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.2022Frontiers in immunology免费全文
  17. Case Report: Overlapping Syndrome of Anti-NMDAR Encephalitis and MOG Inflammatory Demyelinating Disease in a Patient With Human Herpesviruses 7 Infection.2022Frontiers in immunology
  18. Electroconvulsive therapy in a patient with positive anti-NMDA receptor antibodies presenting with isolated psychiatric symptoms: A case report.2022Schizophrenia research
  19. Temporal rank of clinical characteristics and prognosis of anti-N-methyl-d-aspartate receptor encephalitis.2021Brain and behavior
  20. Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case-Control Study.2021Frontiers in immunology
  21. High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis.2021Frontiers in immunology
  22. Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China.2021Neurology(R) neuroimmunology & neuroinflammation
中文论文(未计入)1
  1. [Disease Characteristics, Treatment, and Prognosis of Chinese Patients with Autoimmune Encephalitis: A Retrospective Study].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
早期论文(2016–2020 年)18
  1. Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.2020Acta neuropathologica communications
  2. Reply: Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation.2020Annals of clinical and translational neurology
  3. Risk factors for pneumonia in patients with anti-NMDA receptor encephalitis: A single-center retrospective study.2020Medicine
  4. Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis.2019Acta neurologica Scandinavica
  5. Alterations in the human gut microbiome in anti-N-methyl-D-aspartate receptor encephalitis.2019Annals of clinical and translational neurology
  6. Late-onset anti-N-methyl-d-aspartate receptor encephalitis in China.2018Epilepsy & behavior : E&B
  7. Allergy in patients with anti-N-methyl-d-aspartate receptor encephalitis.2018Epilepsy & behavior : E&B
  8. Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.2018Journal of neurology
  9. Massive idiopathic spontaneous hemothorax complicating anti-N-methyl-d-aspartate receptor encephalitis: A case report.2018Medicine
  10. Risk factors for mortality in patients with anti-NMDA receptor encephalitis: Reply to comment on data sparsity.2017Acta neurologica Scandinavica
  11. Risk factors for mortality in patients with anti-NMDA receptor encephalitis.2017Acta neurologica Scandinavica
  12. Case report of anti-N-methyl-D-aspartate receptor encephalitis in a middle-aged woman with a long history of major depressive disorder.2017BMC psychiatry
  13. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study.2017Epilepsia
  14. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.2017Epilepsy & behavior : E&B
  15. Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis.2017Journal of neurology
  16. Comparisons between Psychiatric Symptoms of Patients with Anti-NMDAR Encephalitis and New-Onset Psychiatric Patients.2017Neuropsychobiology
  17. Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China.2016European journal of neurology
  18. Anti-N-methyl-D-aspartate receptor encephalitis: a common cause of encephalitis in the intensive care unit.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis进行中,不再招募NCT05503264研究中心III期2022-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

成都有 3 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科眼科/神经眼科
牵头的论文3
  1. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.2023Frontiers in immunology
  2. Therapeutic Management of Ocular Ischemia in Takayasu's Arteritis: A Case-Based Systematic Review.2021Frontiers in immunology
  3. Application progress of multiple imaging modalities in Takayasu arteritis.2021The international journal of cardiovascular imaging
早期论文(2016–2020 年)6
  1. Restenosis of Bilateral Aorta-Renal Saphenous Vein Grafts after the Surgical Repair of Takayasu Arteritis-induced Bilateral Renal Arteries Stenosis: Case Report.2020Annals of vascular surgery
  2. Interventional therapy for Takayasu arteritis with pulmonary artery and pulmonary vein stenosis.2020European heart journal
  3. Risk of rupture of an aortorenal vein graft aneurysm after the surgical repair of Takayasu arteritis-induced right renal artery stenosis: A case report and a literature review.2019Medicine
  4. Aneurysmal Degeneration of an Aortorenal Bypass for Takayasu Renal Artery Stenosis: A Novel Endovascular Intervention.2018Annals of vascular surgery
  5. A Case of Takayasu Arteritis With the Ostium of Left Main Coronary Artery Obstructed by Prolapsed Thickened Ascending Aortic Intima.2018The American journal of the medical sciences
  6. Treatment of severe hypertension in a 14-year-old child: Successful blood pressure control with additive administration of captopril, an angiotensin-converting enzyme inhibitor, in a patient with bilateral renovascular hypertension.2017Clinical and experimental hypertension (New York, N.Y. : 1993)

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 14 篇,占 9.2%。

牵头论文
14
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 1120222023: 4420232024: 3320242025: 002025

成都有 5 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经外科儿科
牵头的论文14
  1. High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.2024Parasites & vectors
  2. Epidemiology and Clinical Characteristics of Cerebral Alveolar Echinococcosis in the Tibetan Region of Sichuan, China.2024The American journal of tropical medicine and hygiene
  3. Pictorial review of hepatic echinococcosis: Ultrasound imaging and differential diagnosis.2024World journal of gastroenterology
  4. Two-step resection procedure for advanced hepatic alveolar echinococcosis: First case-series report.2023Asian journal of surgery
  5. Lung and brain recurrence after liver transplantation for advanced alveolar echinococcosis: A case report.2023Asian journal of surgery
  6. Successful laparoscopic anatomical resection of segments V and VIII for hepatic alveolar echinococcosis with diaphragmatic involvement: A case report.2023Asian journal of surgery
  7. Can contrast-enhanced ultrasound differentiate the type of hepatic echinococcosis: cystic echinococcosis or alveolar echinococcosis?2023Parasites & vectors
  8. Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis.2022Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  9. Two-stage hepatectomy combined with middle hepatic vein reconstruction in a patient with complicated hepatic alveolar echinococcosis.2021Asian journal of surgery
  10. Severe hypernatremia in children after surgical resection of hepatic echinococcosis: a rare and potentially fatal complication.2021BMC pediatrics
  11. Application of ex vivo liver resection and autotransplantation in treating Budd-Chiari syndrome secondary to end-stage hepatic alveolar echinococcosis: A case series.2021Medicine
  12. Treatment of retroperitoneal echinococcosis: the experience of a single center.2021Medicine
  13. Triphase contrast-enhanced CT to evaluate indications for autologous liver transplantation in patients with end-stage hepatic alveolar echinococcosis.2021Scientific reports
  14. Hydatid Pulmonary Embolism: A Case Report and Literature Review.2021The American journal of case reports
中文论文(未计入)2
  1. [Relationship Between the Level of Anatomical Risk of Hepatic Alveolar Echinococcosis and Complications after Radical Resection].2022Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  2. [Feasibility of ultrasound radiomics-based models for classification of hepatic echinococcosis].2022Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control
早期论文(2016–2020 年)22
  1. Another case of hepatic alveolar echinococcosis?2020Asian journal of surgery
  2. Individualized biliary reconstruction techniques in autotransplantation for end-stage hepatic alveolar echinococcosis.2020HPB : the official journal of the International Hepato Pancreato Biliary Association
  3. Epidemiological characteristics of hepatic echinococcosis, concurrent cerebral echinococcosis, and pulmonary echinococcosis in Ganzi County, Sichuan Province, China.2020Medicine
  4. Preoperative nutritional evaluation of patients with hepatic alveolar echinococcosis.2020PloS one
  5. Outcomes of different surgical resection techniques for end-stage hepatic alveolar echinococcosis with inferior vena cava invasion.2019HPB : the official journal of the International Hepato Pancreato Biliary Association
  6. Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis.2019International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  7. Remnant Liver-to-Standard Liver Volume Ratio Below 40% is Safe in Ex Vivo Liver Resection and Autotransplantation.2019Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  8. Transhepatic-intrahepatic branches of the portal vein catheterization for ex vivo liver resection and autotransplantation: Two case reports of novel approach to perfuse the liver.2019Medicine
  9. Doughnut sign of hepatic alveolar echinococcosis on FDG PET/CT: Clinical case report.2019Medicine
  10. The role of contrast-enhanced ultrasound in the diagnosis of hepatic alveolar echinococcosis.2019Medicine
  11. Surgical approaches for definitive treatment of hepatic alveolar echinococcosis: results of a survey in 178 patients.2019Parasitology
  12. Vascular infiltration-based surgical planning in treating end-stage hepatic alveolar echinococcosis with ex vivo liver resection and autotransplantation.2019Surgery
  13. Residual cavity hydrops initially misdiagnosed as recurrent hepatic echinococcosis.2019The Lancet. Infectious diseases
  14. Novel techniques and preliminary results of ex vivo liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis: A study of 31 cases.2018American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  15. The choose of different surgical therapies of hepatic alveolar echinococcosis: A single-center retrospective case-control study.2018Medicine
  16. Ultrasonographic findings of small lesion of hepatic alveolar echinococcosis.2017Acta tropica
  17. Risk factors and a simple model for predicting bile leakage after radical hepatectomy in patients with hepatic alveolar echinococcosis.2017Medicine
  18. The association of hypernatremia and hypertonic saline irrigation in hepatic hydatid cysts: A case report and retrospective study.2017Medicine
  19. Two-stage hepatectomy for multiple giant alveolar echinococcosis.2017Medicine
  20. Hepatectomy for patients with alveolar echinococcosis: Long-term follow-up observations of 144 cases.2016International journal of surgery (London, England)
  21. Multiorgan resection with inferior vena cava reconstruction for hepatic alveolar echinococcosis: A case report and literature review.2016Medicine
  22. Hepatic Vein Injuries During Laparoscopic Hepatectomy.2016Surgical laparoscopy, endoscopy & percutaneous techniques
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. 5G Remote Robotic Surgery for Hepatic Echinococcosis in High-Altitude Region即将招募NCT07551063牵头方早期I期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 31 篇,占 3.1%。

牵头论文
31
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 121220232024: 6620242025: 772025

成都有 16 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科风湿免疫科消化/肝病科临床试验/研究机构
牵头的论文31
  1. Biomimetic Topological Micropattern Arrays Regulate the Heterogeneity of Cellular Fates in Lung Fibroblasts between Fibrosis and Invasion.2025ACS nano
  2. Discovery of novel capsaicin analogs as TRPV1 inhibitors for the treatment of idiopathic pulmonary fibrosis.2025European journal of medicinal chemistry
  3. The Ketone Body β-Hydroxybutyrate Mitigates the Ferroptosis of Alveolar Epithelial Cells Type II in Bleomycin-Induced Pulmonary Fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  4. CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS.2025JCI insight
  5. Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.2025PloS one
  6. Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.2025Respiratory research
  7. The value of macrolides in the adjuvant treatment of pulmonary fibrosis: maybe a panacea.2025Therapeutic advances in respiratory disease
  8. Tetrahedral Framework Nucleic Acids Delivery of Pirfenidone for Anti-Inflammatory and Antioxidative Effects to Treat Idiopathic Pulmonary Fibrosis.2024ACS nano
  9. INTEGRIS-IPF: A New Hope for Tomorrow.2024American journal of respiratory and critical care medicine
  10. Acute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China.2024European journal of medical research
  11. Buyang Huanwu decoction ameliorates bleomycin-induced pulmonary fibrosis in rats by attenuating the apoptosis of alveolar type II epithelial cells mediated by endoplasmic reticulum stress.2024Journal of ethnopharmacology
  12. Authors' Reply to Letter to the Editor Regarding the Article "Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: a Two-Sample Mendelian Randomization Study".2024Lung
  13. Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes.2024Respiratory research
  14. Diagnostic and prognostic value of secreted phosphoprotein 1 for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  15. Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.2023Bioorganic chemistry
  16. AAV9-Tspyl2 gene therapy retards bleomycin-induced pulmonary fibrosis by modulating downstream TGF-β signaling in mice.2023Cell death & disease
  17. Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.2023European journal of medicinal chemistry
  18. Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.2023European journal of medicinal chemistry
  19. Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.2023European journal of medicinal chemistry
  20. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesRCT
  21. Diabetic endothelial microangiopathy and pulmonary dysfunction.2023Frontiers in endocrinology
  22. Decreased Th1 Cells and Increased Th2 Cells in Peripheral Blood Are Associated with Idiopathic Inflammatory Myopathies Patients with Interstitial Lung Disease.2023Inflammation
  23. Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.2023Journal of advanced research
  24. Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: A Two-Sample Mendelian Randomization Study.2023Lung
  25. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.2023Respiratory medicine
  26. Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis.2022American journal of physiology. Lung cellular and molecular physiology
  27. Role of Circular RNAs in Pulmonary Fibrosis.2022International journal of molecular sciences
  28. Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.2022Respiratory research
  29. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.2021European journal of medicinal chemistry
  30. Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.2021Medicine
  31. Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis.2021PloS one
中文论文(未计入)1
  1. [Advances in research on the relationship between changes in cellular metabolism and lung diseases].2021Zhonghua wei zhong bing ji jiu yi xue
早期论文(2016–2020 年)5
  1. Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.2020European journal of medicinal chemistry
  2. Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis.2020Frontiers in public health
  3. Mitochondrial dysfunction and chronic lung disease.2019Cell biology and toxicology
  4. In Silico Detection and Characterization of microRNAs and Their Target Genes in microRNA Microarray Datasets from Patients with Systemic Sclerosis-Interstitial Lung Disease.2019DNA and cell biology
  5. Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.2016Molecular bioSystems
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  3. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06230822研究中心I期2024-03 启动
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  7. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  8. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  9. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  11. A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT04419506研究中心II期2020-07 启动
  12. Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis已完成NCT01619085研究中心III期2012-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 2 篇,占 4.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

成都有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文2
  1. Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis.2022Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  2. Sirolimus in the treatment of kaposiform lymphangiomatosis.2021Orphanet journal of rare diseases
早期论文(2016–2020 年)1
  1. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.2020Respiratory research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 60 篇,占 7.7%。

牵头论文
60
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 111120222023: 141420232024: 161620242025: 882025

成都有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    分期
    I期
    开始
    2024-12
    登记号
    NCT06556394

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、成都、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科影像/核医学科
牵头的论文60
  1. Untargeted metabolomics based on LC-MS and GC-MS reveal metabolic reprogramming and putative biomarkers in amyotrophic lateral sclerosis.2026Chinese medical journal
  2. Loss of Y chromosome and its implications in male amyotrophic lateral sclerosis: insights from the UK Biobank.2025BMC medicine
  3. Genetically Predict Diet-derived Antioxidants and Risk of Neurodegenerative Diseases Among Individuals of European Descent: A Mendelian Randomization Study.2025Brain and behavior
  4. Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis.2025Molecular neurobiology
  5. Association between Psychiatric Disorders and Amyotrophic Lateral Sclerosis: A Prospective Cohort Study from the UK Biobank.2025Neuroepidemiology
  6. Association between metabolic syndrome, its individual components and progression of amyotrophic lateral sclerosis.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  7. Association of creatinine level with neurodegenerative disorders: a prospective cohort study and Mendelian randomization analysis.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Viral infections and the risk of neurodegenerative diseases: a comprehensive meta-analysis and systematic review.2025Translational psychiatry
  9. Association between sleep and ALS-FTSD: A Prospective Cohort Study based on 396,918 UK biobank participants.2025Translational psychiatry
  10. Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis.2024Amyotrophic lateral sclerosis & frontotemporal degeneration
  11. The C9orf72-SMCR8 complex suppresses primary ciliogenesis as a RAB8A GAP.2024Autophagy
  12. TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.2024BMC medicine
  13. Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.2024Brain and behavior
  14. Differential cortical gray matter changes in early- and late-onset patients with amyotrophic lateral sclerosis.2024Cerebral cortex (New York, N.Y. : 1991)
  15. Genotype-phenotype correlation of SQSTM1 variants in patients with amyotrophic lateral sclerosis.2024Journal of medical genetics
  16. Amyotrophic lateral sclerosis patients with various gene mutations show diverse motor phenotypes and survival in China.2024Journal of medical genetics
  17. Clinical and genetic characteristics of ALS patients with variants in genes regulating DNA methylation.2024Journal of neurology
  18. Genome-wide DNA methylation analysis related to ALS patient progression and survival.2024Journal of neurology
  19. The Long Non-Coding RNA NR3C2-8:1 Promotes p53-Mediated Apoptosis through the miR-129-5p/USP10 Axis in Amyotrophic Lateral Sclerosis.2024Molecular neurobiology
  20. Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.2024Molecular neurobiology
  21. Lnc-HIBADH-4 Regulates Autophagy-Lysosome Pathway in Amyotrophic Lateral Sclerosis by Targeting Cathepsin D.2024Molecular neurobiology
  22. Rare DNAJC7 Variants May Play a Minor Role in Chinese Patients with ALS.2024Molecular neurobiology
  23. Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis.2024Molecular neurobiology
  24. Total physical activity, plant-based diet and neurodegenerative diseases: A prospective cohort study of the UK biobank.2024Parkinsonism & related disorders
  25. Downregulation of Lnc-ABCA12-3 modulates UBQLN1 expression and protein homeostasis pathways in amyotrophic lateral sclerosis.2024Scientific reports
  26. BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy.2023Acta pharmacologica Sinica
  27. Association between vascular risk factors and cognitive impairment in amyotrophic lateral sclerosis: a case-control study.2023Amyotrophic lateral sclerosis & frontotemporal degeneration
  28. Genetic Modifiers of Age at Onset for Amyotrophic Lateral Sclerosis: A Genome-Wide Association Study.2023Annals of neurology
  29. TBK1 variants in Chinese patients with amyotrophic lateral sclerosis: Genetic analysis and clinical features.2023European journal of neurology
  30. Multisite chronic pain and the risk of autoimmune diseases: A Mendelian randomization study.2023Frontiers in immunology
  31. Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis.2023Human genomics
  32. Identifying novel genes for amyotrophic lateral sclerosis by integrating human brain proteomes with genome-wide association data.2023Journal of neurology
  33. Physical activity as risk factor in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2023Journal of neurology
  34. Genetic and Phenotypic Spectrum of Amyotrophic Lateral Sclerosis Patients with CCNF Variants from a Large Chinese Cohort.2023Molecular neurobiology
  35. Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis.2023Molecular neurodegeneration
  36. Genetic and clinical characteristics of ALS patients with NEK1 gene variants.2023Neurobiology of aging
  37. ALS-linked C9orf72-SMCR8 complex is a negative regulator of primary ciliogenesis.2023Proceedings of the National Academy of Sciences of the United States of America
  38. Venous blood parameters in determination of respiratory impairment in amyotrophic lateral sclerosis.2023Scientific reports
  39. Sleep in amyotrophic lateral sclerosis: A systematic review and meta-analysis of polysomnographic findings.2023Sleep medicine
  40. A case of juvenile-onset amyotrophic lateral sclerosis with a de novo frameshift FUS gene mutation presenting with bilateral abducens palsy.2022Amyotrophic lateral sclerosis & frontotemporal degeneration
  41. Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.2022BMC medicine
  42. Spatial-temporal pattern of propagation in amyotrophic lateral sclerosis and effect on survival: A cohort study.2022European journal of neurology
  43. A Prediction Model for Peak Expiratory Flow Derived From Venous Blood Biomarkers and Clinical Factors in Amyotrophic Lateral Sclerosis.2022Frontiers in public health
  44. Lack of association of TP73 rare variants with amyotrophic lateral sclerosis in a Chinese cohort.2022Human genomics
  45. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population.2022Journal of medical genetics
  46. The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A.2022Journal of neuroinflammation
  47. The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients.2022Molecular neurobiology
  48. Mutation Screening of TFG in α-Synucleinopathy and Amyotrophic Lateral Sclerosis.2022Movement disorders : official journal of the Movement Disorder Society
  49. Genetic analysis of and clinical characteristics associated with ANXA11 variants in a Chinese cohort with amyotrophic lateral sclerosis.2022Neurobiology of disease
  50. The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure.2022Small GTPases
  51. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases.2021BMC medicine
  52. Early weight instability is associated with cognitive decline and poor survival in amyotrophic lateral sclerosis.2021Brain research bulletin
  53. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis.2021EBioMedicine
  54. Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.2021Health and quality of life outcomes
  55. Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2021Journal of neurology, neurosurgery, and psychiatry
  56. The Evaluation of Pain with Nociceptive and Neuropathic Characteristics from Three Different Perspectives in Amyotrophic Lateral Sclerosis Patients: A Case Controlled Observational Study in Southwestern China.2021Neural plasticity
  57. Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study.2021Neurobiology of aging
  58. Mutation screening and burden analysis of GLT8D1 in Chinese patients with amyotrophic lateral sclerosis.2021Neurobiology of aging
  59. Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis.2021Translational neurodegeneration
  60. Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.2021Translational neurodegeneration
中文论文(未计入)1
  1. [Advance in research on biomarkers for amyotrophic lateral sclerosis].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)38
  1. Effects of Exercise in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.2020American journal of physical medicine & rehabilitation
  2. Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. The C9orf72-SMCR8-WDR41 complex is a GAP for small GTPases.2020Autophagy
  4. LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice.2020Cell death and differentiation
  5. MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis.2020Journal of cellular and molecular medicine
  6. Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study.2020Molecular neurobiology
  7. Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a.2020Proceedings of the National Academy of Sciences of the United States of America
  8. Patterns of brain regional functional coherence in cognitive impaired ALS.2020The International journal of neuroscience
  9. Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  10. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  11. Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis.2019Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  12. Mutation screening of the KIF5A gene in Chinese patients with amyotrophic lateral sclerosis.2019Journal of neurology, neurosurgery, and psychiatry
  13. Unique characteristics of the genetics epidemiology of amyotrophic lateral sclerosis in China.2019Science China. Life sciences
  14. An association study between SCFD1 rs10139154 variant and amyotrophic lateral sclerosis in a Chinese cohort.2018Amyotrophic lateral sclerosis & frontotemporal degeneration
  15. Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry.2018Brain research bulletin
  16. Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations.2018Journal of molecular neuroscience : MN
  17. Altered white matter microarchitecture in amyotrophic lateral sclerosis: A voxel-based meta-analysis of diffusion tensor imaging.2018NeuroImage. Clinical
  18. Mutation screening of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis/frontotemporal dementia.2018Neurobiology of aging
  19. Meta-analysis of the association between ZNF512B polymorphism rs2275294 and risk of amyotrophic lateral sclerosis.2018Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  20. The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.2018Neuroscience letters
  21. Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population.2018Neuroscience letters
  22. Absence of association of the Ala58Val (rs17571) CTSD gene variant with Parkinson's disease or amyotrophic lateral sclerosis in a Han Chinese population.2018Neuroscience letters
  23. White matter volume loss in amyotrophic lateral sclerosis: A meta-analysis of voxel-based morphometry studies.2018Progress in neuro-psychopharmacology & biological psychiatry
  24. Why might ALS have negative effects on patients with out-of-hospital cardiac arrest?2018The American journal of emergency medicine
  25. [Roles of exosomes in Parkinson's disease and amyotrophic lateral sclerosis].2018Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  26. Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study.2017Journal of clinical nursing
  27. Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.2017Journal of the neurological sciences
  28. HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.2017Journal of the neurological sciences
  29. Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis.2017Molecular neurobiology
  30. Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival.2017Molecular neurodegeneration
  31. Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: a case-control study and literature review.2017Scientific reports
  32. Associations between neuropsychiatric symptoms and cognition in Chinese patients with amyotrophic lateral sclerosis.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  33. Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.2016BMC neurology
  34. Mutational analysis of CHCHD2 in Chinese patients with multiple system atrophy and amyotrophic lateral sclerosis.2016Journal of the neurological sciences
  35. SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population.2016Journal of the neurological sciences
  36. Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis.2016Neurobiology of aging
  37. Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  38. No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population.2016Neuroscience letters
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation正在招募NCT06556394研究中心I期2024-12 启动
  2. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis即将招募NCT06645197研究中心早期I期2024-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

成都有 3 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
牵头的论文1
  1. Effects of physical therapy on motor ability in patients with spinal muscular atrophy III: a study protocol for a randomised controlled trial.2025BMJ open
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 5 篇,占 6.9%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

成都有 2 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

成都有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

成都有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.5%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 2220242025: 112025

成都有 5 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

成都有 4 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 34 篇,占 4.6%。

牵头论文
34
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 8820222023: 6620232024: 6620242025: 662025

成都有 9 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科病理/检验科影像/核医学科
牵头的论文34
  1. 2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation.2025BMC microbiology
  2. Particulate matter exposure and end-stage renal disease risk in IgA nephropathy.2025Frontiers of medicine
  3. High systemic inflammatory response index (SIRI) is an independent risk factor for poor outcome in IgA nephropathy patients.2025International urology and nephrology
  4. Risk Stratification in Immunoglobulin A Nephropathy Using Network Biomarkers: Development and Validation Study.2025Journal of medical Internet research
  5. Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.2025Renal failure
  6. Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.2025Renal failure
  7. Personalized decision support system for tailoring IgA nephropathy treatment strategies.2024European journal of internal medicine
  8. Demographic distribution analysis of different glomerular diseases in Southwest China from 2008 to 2022.2024International urology and nephrology
  9. Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy.2024Kidney & blood pressure research
  10. Combined Effects of the Serum IgA/C3 Ratio and Glomerular C3 Staining on the Renal Outcome in Adult Immunoglobulin A Nephropathy.2024Kidney & blood pressure research
  11. The clinical and pathological evaluation of patients with immunoglobulin A nephropathy by diffusion tensor imaging and intravoxel incoherent motion diffusion-weighted imaging.2024The British journal of radiology
  12. Nephrotic proteinuria and hematuria with newly diagnosed IgA nephropathy after liver transplant: A case report.2024Transplant immunology
  13. Altered serum metabolic profile in patients with IgA nephropathy.2023Clinica chimica acta; international journal of clinical chemistry
  14. Association of obesity with the development of end stage renal disease in IgA nephropathy patients.2023Frontiers in endocrinology
  15. Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis.2023Frontiers in immunology
  16. Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN.2023International immunopharmacology
  17. Uric acid-based ratios for predicting renal failure in Chinese IgA nephropathy patients.2023International journal of medical sciences
  18. Characterization of site-specific N-glycosylation signatures of isolated uromodulin from human urine.2023The Analyst
  19. IgA Nephropathy in a Patient With Metastatic Carcinoma of Unknown Primary: Findings on 18F-FDG PET/MRI.2022Clinical nuclear medicine
  20. Prognostic Value of Triglyceride to High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in IgA Nephropathy Patients.2022Frontiers in endocrinology
  21. Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor.2022Frontiers in immunology
  22. Association of genetic polymorphisms in IL-23R and IL-17A with the susceptibility to IgA nephropathy in a Chinese Han population.2022Genes and immunity
  23. Prognostic value of the albumin-to-fibrinogen ratio (AFR) in IgA nephropathy patients.2022International immunopharmacology
  24. The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation.2022Journal of immunology research
  25. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.2022Journal of translational medicine
  26. Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy.2022Renal failure
  27. Cigarette smoking may accelerate the progression of IgA nephropathy.2021BMC nephrology
  28. Mesangial IgM deposition predicts renal outcome in patients with IgA nephropathy: a multicenter, observational study.2021Clinical and experimental medicine
  29. Epigenome-wide association study and network analysis for IgA Nephropathy from CD19+ B-cell in Chinese Population.2021Epigenetics
  30. High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.2021Frontiers in immunology
  31. Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients.2021International journal of medical sciences
  32. Sex disparities in IgA nephropathy: a retrospective study in Chinese patients.2021International urology and nephrology
  33. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.2021International urology and nephrology
  34. A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy.2021Scientific reports
早期论文(2016–2020 年)13
  1. Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population.2020International immunopharmacology
  2. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.2020Medicine
  3. Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.2020Renal failure
  4. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.2020Scientific reports
  5. [Effect of serum IgA/C3 and glomerular C3 staining on clinical prognosis in patients with IgA nephropathy].2020Zhonghua yi xue za zhi
  6. Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.2019Clinical and experimental medicine
  7. IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy.2019Journal of translational medicine
  8. Crescents and Global Glomerulosclerosis in Chinese IgA Nephropathy Patients: A Five-Year Follow-Up.2019Kidney & blood pressure research
  9. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.2018Kidney & blood pressure research
  10. Interleukin 18 -607 A/C Gene Polymorphism is Associated With Susceptibility to IgA Nephropathy in a Chinese Han Population.2017Applied immunohistochemistry & molecular morphology : AIMM
  11. MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy.2017International urology and nephrology
  12. The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).2016Medicine
  13. Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.2016Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  2. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  4. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  5. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  6. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

成都有 1 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Molecular regulations and therapeutic targets of Gaucher disease.2018Cytokine & growth factor reviews

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

成都有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta进行中,不再招募NCT05972551研究中心III期2024-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 3.7%。

牵头论文
11
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 4420242025: 112025

成都有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科神经内科影像/核医学科
牵头的论文11
  1. Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients.2025European journal of radiology
  2. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.2024Alimentary pharmacology & therapeutics
  3. Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.2024European radiology
  4. Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.2024Journal of hepatology
  5. Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome.2024Journal of translational medicine
  6. Factors and cytokine signatures associated with the response to therapy in patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome: a real-world study.2023Chinese medical journal
  7. Hematologic traits and primary biliary cholangitis: a Mendelian randomization study.2023Journal of human genetics
  8. Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional Mendelian randomization study.2023Scientific reports
  9. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome.2022World journal of gastroenterology
  10. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis.2021Canadian journal of gastroenterology & hepatologyRCT
  11. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.2021Digestive diseases (Basel, Switzerland)
中文论文(未计入)1
  1. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].2023Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
早期论文(2016–2020 年)9
  1. Primary biliary cholangitis with autoimmune hepatitis features: What's the appropriate criteria to evaluate the treatment-response?2020Annals of hepatology
  2. Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.2020Clinical rheumatology
  3. Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis.2020Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  4. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.2019Canadian journal of gastroenterology & hepatology
  5. Severe anemia caused by hereditary hemorrhagic telangiectasia in a patient with Sjögren's syndrome and primary biliary cirrhosis.2019Chinese medical journal
  6. Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.2019European journal of gastroenterology & hepatology
  7. Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China.2019Scientific reports
  8. Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.2018Canadian journal of gastroenterology & hepatology
  9. Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients.2017Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1状态不明NCT04618575牵头方IV期2021-03 启动
  2. Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy状态不明NCT04376528牵头方IV期2021-06 启动
  3. Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II状态不明NCT04617561牵头方IV期2020-11 启动
  4. A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis状态不明NCT03345589牵头方IV期2018-01 启动
  5. The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital已完成NCT03322943牵头方2016-01 启动
  6. A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome状态不明NCT04933292牵头方(推断)IV期2021-06 启动
  7. Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital已完成NCT02917408牵头方(推断)2016-09 启动
  8. Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome状态不明NCT02936596牵头方(推断)不分期2016-12 启动
  9. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  10. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  11. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  12. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 3.0%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

成都有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 5 篇,占 8.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 1120232024: 0020242025: 112025

成都有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文5
  1. Global birth prevalence of major congenital anomalies: a systematic review and meta-analysis.2025BMC public health
  2. Fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: systematic review and meta-analysis.2023Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  3. A rare Bochdalek hernia in an adult: a case report.2021BMC surgery
  4. Emergency Management of Acute Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.2021Pediatric emergency care
  5. Do B-type natriuretic peptide levels accurately predict outcome in infants with congenital diaphragmatic hernia?2021The Journal of pediatrics
早期论文(2016–2020 年)4
  1. Another type of diaphragmatic hernia to remember: parahiatal hernia.2020ANZ journal of surgery
  2. Thoracoscopic Treatment of Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.2019Journal of laparoendoscopic & advanced surgical techniques. Part A
  3. Minimally invasive surgery for congenital diaphragmatic hernia: a meta-analysis.2016Hernia : the journal of hernias and abdominal wall surgery
  4. [OBSERVATION OF EFFECTIVENESS OF THORACOSCOPIC SURGERY FOR LATEPRESENTING CONGENITAL DIAPHRAGMATIC HERNIA].2016Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

成都有 2 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 4 篇,占 7.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

成都有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

成都有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
牵头的论文2
  1. Long-Term Attenuation of Vascular Hyperpermeability in a Hereditary Angioedema Mouse Model by Adenine Base Editing.2026Allergy
  2. A 42-Year Delay in Diagnosing Hereditary Angioedema: A Case Report.2024Dermatitis : contact, atopic, occupational, drug
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Phase 2 in Adult Subjects With Hereditary Angioedema进行中,不再招募NCT06846398研究中心II期2025-02 启动
  2. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

成都有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

四川大学华西医院

West China Hospital

成都

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
West China Hospital of Sichuan University; Sichuan University West China Hospital; West China Hospital Sichuan University; West China Hospital Sichuan University Chengdu Sichuan China; Digestive Endoscopic Center of West China Hospital; Biomedical Big Data Center of West China Hospital; Operation Room of West China Hospital; Chengdu Shang Jin Nan Fu Hospital West China Hospital

提出更正下载数据